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Epidemiology
Multiple Sclerosis is the most common disabling condition affecting young 
adults (Confavreux et al. 1430-38). In the Netherlands the prevalence is 
estimated to be about 100 patients per 100.000 inhabitants. Every week 
3 new MS patients are being diagnosed in the Netherlands. The mean 
age at onset is approximately 30 years. Females are twice as frequently 
affected as men (Compston and Coles 1502-17). The incidence varies 
widely worldwide depending on both genetic and geographical factors; 
in general the highest incidence is found at a larger distance from the 
equator.
Clinical presentation
The majority of patients present with a first acute or sub-acute episode 
of symptoms, a presentation that is called a ‘clinically isolated syndrome’ 
(CIS). The most frequently involved areas  are the optic nerve, spinal 
cord and/or  brainstem,  respectively causing decreased vision, pareses 
and/or sensory disorders in the limbs and diplopia. In patients with a 
CIS, around  30-70% develop MS and have the relapsing / remitting 
type of the disease (RR-MS) (Fisniku et al. 808-17). This disease type 
is characterized by subsequent episodes of symptoms or ‘relapses’ with 
usually full or partial, but sometimes no recovery. The duration of the 
periods in between symptoms is highly variable and there is no clinical 
disease progression between relapses. Eventually, the majority of these 
patients will also gradually worsen in between relapses. This stage of the 
disease with gradual worsening, in combination with relapses, is called 
secondary progressive multiple sclerosis (SP-MS) (Lublin and Reingold 
907-11) (Figure 1).
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Ten to fifteen percent of patients never experience a relapse and present 
with slowly evolving progressive disease, usually  consisting of spinal 
cord symptoms. These patients have the primary-progressive type of MS 
(PP-MS) (Wolinsky 145-52).
Genetic background
MS is most likely caused by a combination of genetic  and environmental 
factors.  The disease is more prevalent amongst Western Europeans, 
and as mentioned before,  prevalence increases with the distance from 
the equator.   However,  some ethnic groups seem to be resistant to 
the disease even though they live in areas of high prevalence. Also, 
migration during childhood from areas with a high to areas with a low 
incidence is associated with a reduced risk. Genetic factors are further 
demonstrated by the familial occurrence of MS. 15-20% of patients report 
a family history of MS, which is higher  than would be expected by chance 
(Sawcer 3118-31). The disease is more frequent in siblings, who have 
a 5% chance of the disease, as opposed to for example 1% chance in 
third degree relatives. A consistent association has been shown between 
MHC alleles DR15, DQ6 and MS. Due to the high prevalence of these 
Figure 1. Schematic illustration of the course of the different types of MS. The X-axis 
represents time and the Y-axis represents neurological disability.
RR = relapsing remitting, PP = primary progressive, SP = secondary progressive, 
PR = progressive relapsing
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alleles in the general population however, it is not possible to apply this 
knowledge in clinical practice (Compston and Coles 1502-17;Rejdak, 
Jackson, and Giovannoni 79-104).
Pathophysiology
Multiple sclerosis is a multifocal demyelinating disease affecting white 
as well as grey matter. The disease is characterized by lesions with 
inflammation, demyelination and axonal loss. In the initial phase in the 
disease there is probably migration of auto reactive lymphocytes across 
the blood brain barrier. In combination with local regulatory failure, plaques 
are being formed in localized areas in the brain and the spinal cord. It is 
unclear what the antigen specificity of the involved immune responses 
is. Locally different inflammatory cells gather and pro inflammatory 
cytokines enhance inflammation by activating microglia, which in turn 
contact oligodendrocytes. In acute lesions a heterogeneous pathology 
is observed with astrocytes, activated phagocytic macrophages, T-cells, 
transected axons and myelin degradation products. These myelin 
degradation products are positive for myelin oligodendrocyte glycoprotein 
(MOG) and myelin associated glycoprotein (MAG) initially, and later for 
major myelin proteins such as myelin basic protein (MBP) and proteolipid 
protein (PLP). Acute lesions are encountered chiefly in patients with 
relapses. In chronic not actively inflamed lesions, an inactive center is 
surrounded by an edge of activated macrophages, microglia and very 
few myelin degradation products. These lesions are observed especially 
in patients with progressive disease (Hu and Lucchinetti 439-53). 
Therapy
Currently, there is no cure for MS. However, several drugs are available 
that suppress disease activity, and some of these have also been shown 
to slow disease progression. Most frequently used medication includes 
interferon β which has been shown to delay the second clinical event 
in CIS patients (Kappos et al. 1242-49) (Comi et al. 1576-82;Jacobs et 
al. 898-904), to decrease the number and severity of relapses in patients 
with RR-MS, and seems to delay clinical disability (Kappos et al. 389-97). 
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Interferon β requires the patient to self-inject on at least a weekly basis. A 
comparable regularly used first line drug is glatiramer acetate. Further 
medication includes natalizumab, a monoclonal antibody against α4 
integrin that is more effective than interferon (Rudick et al. 911-23). It is 
used as second line drug due to the occurrence of progressive multifocal 
encephalopathy (PML), a rare but potentially fatal side effect that occurs 
in 1 out of every thousand patients treated with the drug. Natalizumab is 
administered as monthly intravenous infusions. Other second line drugs 
include Mitoxantrone. Presently new drugs are emerging. Among them 
the orally administered Fingolimod (Cohen et al. 402-15) and Cladribine 
(Giovannoni et al. 329-37). None of these drugs have been shown 
effective in the progressive phase of the disease, for which presently no 
disease modifying therapy is available. 
1.2 Diagnosis
Presently, no single diagnostic test for MS exists. Therefore diagnostic 
guidelines have been defined. A definite diagnosis of MS requires 
evidence of dissemination in space and time in terms of central nervous 
system lesions (Schumacher GA et al. 552-68). Initially such evidence was 
based almost entirely on clinical findings, and to a lesser extent, on the 
results of paraclinical evidence, at that time principally cerebrospinal fluid 
(Poser et al. 227-31). Classically, to diagnose MS, at least two relapses 
(“dissemination in time”, DIT) are required, including objective clinical 
evidence of more than one separate lesion in the CNS (“dissemination in 
space”, DIS); this is called clinically definite MS (CDMS). Whether (para)
clinical evidence can best be explained by one or by more underlying 
anatomical lesions, and thus provide evidence for dissemination in 
space, was not defined further and left to the diagnosing physician. The 
most sensitive paraclinical test is Magnetic Resonance Imaging (MRI), 
showing abnormalities in approximately 95% of patients with CDMS and 
valuable in ruling out other neurological diseases. With detailed MRI 
criteria (Barkhof et al. 2059-69;Tintore et al. 702-06) requiring an  MRI to 
show a minimum number of lesions located at  MS specific locations  and 
showing specific activity, it was possible to substitute part of the clinical 
evidence and consequently  provide additional evidence for DIS (table 
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1) and DIT. With these MRI criteria, the second relapse was no longer 
required in a substantial number of patients; the diagnosis could now be 
made after the first relapse.  
Box 1. Explanation of sensitivity and specificity
In 2001 (McDonald et al. 121-27) these detailed Magnetic Resonance 
Imaging criteria were incorporated to improve diagnostic accuracy and to 
allow for an earlier diagnosis (Table 2). It was then shown that the majority 
of MS patients have spinal cord lesions on MRI, whereas patients with 
other neurological diseases seldom have such lesions (Bot et al. 46-56). 
Another study (Dalton et al. 673-76) demonstrated that a new T2 lesion 
on an MRI made on an average   of 5 weeks after disease onset, was 
sufficient proof for the dissemination in time criterion. To incorporate the 
use of spinal cord and  DIT criterion, and clarify original definitions, the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic tests: sensitivity and specificity 
Specificity is the proportion of patients without the disease who have a 
negative test result. 
 
Sensitivity is the proportion of patients with the disease who have a 
positive test result (i.e. the percentage of sick people who are correctly 
identified by the test as having the condition). 
 
Sensitivity and specificity are independent of the prevalence of the 
disease in the studied population. For example positive and negative 
predictive value, in contrast, are dependent of the prevalence of the 
disease in the studied population. A diagnostic test with high specificity 
is valuable to confirm a diagnosis, whereas a test with high sensitivity is 
important for ruling out the disease 
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diagnostic guidelines were again revised in 2005 (Polman et al. 840-46). 
Dissemination in time could now be established  by the presence of a 
new T2 lesion on an MRI made at least 1 month after disease onset.
Table 1. Magnetic Resonance Imaging Criteria for Brain Abnormality 
Three of four of the following 
1. One gadolinium-enhancing lesion or nine T2-hyperintense lesions if there is no 
gadolinium enhancing lesion 
2. At least one infratentorial lesion 
3. At least one juxtacortical lesion 
4. At least three periventricular lesions 
Note: One spinal cord lesion can be substituted for one brain lesion. Data from Barkhof et 
al and Tintoré et al. 
In spite of the increasing role for MRI in diagnosing MS, clinical 
data remain essential.  Whereas rules for the interpretation of MRI data 
are defined in detail, no such clinical classification existed. The need 
for additional paraclinical investigations such as MRI, depends on the 
available clinical information. As  more evidence for DIS and DIT can 
be assessed clinical, less paraclinical information is needed. In order to 
accomplish dissemination in space criteria clinically for example, there 
has to be objective evidence of 2 or more clinical lesions (McDonald et 
al. 121-27). Whether symptoms and signs can be explained by 2 or more 
clinical lesions however, is left to the diagnosing physician and has been 
shown to vary widely (Uitdehaag et al. 227-31). Additionally, knowledge 
of factors that predict disease progression, especially in the early stages 
of the disease, is limited but of increasing importance as more therapy 
becomes available that may be beneficial in the early disease stages. 
A clinical classification system to define dissemination in space in more 
detail  (Figure 2) was proposed to provide further guidance on this subject. 
In chapter 3.1 and 3.2 we evaluated the relation between this clinical 
classification (Uitdehaag et al. 227-31) and MS related abnormalities on 
brain MRI. This clinical classification system defines disease onset as 
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monofocal (clinical evidence of one lesion in the central nervous system) 
or multifocal (clinical evidence of more than one lesion). Besides its 
diagnostic value, such a classification system might also have prognostic 
value. 
1.3 Prognosis
Multiple sclerosis is a progressive disease where accumulation of 
disease activity will be present in most patients after years as physical 
and/or cognitive impairment. After 2 years of follow up, approximately 
50% of CIS patients meet the diagnostic criteria for MS. After 20 years 
this is more than 80% (Fisniku et al. 808-17). Although the majority of 
patients will consequently  be diagnosed with MS, a minority of patients 
will remain CIS.  As disease modifying agents have repeatedly proven to 
delay a second relapse (Comi et al. 1576-82;Comi et al. 1503-11;Jacobs 
et al. 898-904;Kappos et al. 1242-49;Polman et al. 899-910), it is often 
recommended  to start disease modifying therapy after the first relapse. 
However, as a minority of patients have little or no further disease 
progression after their first relapse (thus remain CIS patients) without 
therapy, it would be useful to be able to identify either such patients, or, 
vice versa, patients who have progressive disease activity. However, few 
clinical prognostic factors have been described. 
1.4 Outline of this thesis
Chapter 2 focuses on specificity of diagnostic criteria for MS. First (2.1) 
the differentiating value between MS and other neurological diseases of 
the MRI criteria for DIS as incorporated in the 2001 McDonald diagnostic 
criteria for dissemination in space are compared to the AAN proposed 
criteria and then (2.2) to the criteria as proposed by Swanton et al. along 
with  the 2005 revisions of the McDonald criteria, in a group of patients 
initially suspected of MS who were eventually  diagnosed with another 
disease. Chapter 2.3 describes the frequency of a neurological diagnosis 
7 years after initial referral for a possible MS diagnosis in patients in 
whom no definite diagnosis was initially made. Chapter 2.4 describes a 
case report which illustrates the importance of a careful interpretation of 
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Figure 2. Standardize stepwise evaluation schema (Uitdehaag et al. 227-31)
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medical history and physical examination in order to distinguish MS from 
other diseases. Chapter 3 focuses on a previously described clinical 
classification system (fig 2), which translates signs and symptoms into 
underlying lesions in a standardized way in patients who present with a 
first episode suggestive of MS. This classification system was studied in 
patients included in the BENEFIT (Betaferon in Newly Emerging Multiple 
Sclerosis for Initial Treatment) trial, a double blind placebo controlled 
multicenter study designed to study the efficacy, safety and tolerability 
of interferon beta-1b. Four hundred and eighty seven patients were 
randomized in this trial, and randomly assigned in a 5:3 ratio to either 
interferon beta-1b or placebo. At study entry each patient was classified 
centrally as mono or multifocal according to the above mentioned 
classification system. Patients were scheduled to  receive treatment 
with placebo or interferon for two years or until CDMS according to the 
modified Poser criteria. After completing the two year double blind study, 
all patients were eligible to enroll in a single arm (interferon beta-1b) 
follow up study with a 3 year extension (and thus 5 years total duration) 
designed to explore the longer term impact of early versus delayed 
treatment with interferon beta-1b (Kappos et al. 1242-49). In chapter 3.1 
we first concentrate on the meaningfulness of this classification system 
by relating it to MRI measures for disease progression. In chapter 3.2 
the prognostic value of this classification system for CDMS is assessed 
and compared to MRI abnormalities that are a risk factor for CDMS. 
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Abstract:
Retrospectively,  we assessed the specificity of two proposed magnetic 
resonance imaging (MRI) criteria for multiple sclerosis (MS) in patients 
suspected of MS but who ultimately receive another diagnosis. Brain 
MRIs of  28 patients mixed with 28 MRIs of MS patients from the 
same cohort of 377 consecutively referred patients were scored by a 
neuroradiologist masked for the final diagnosis. 
The criteria for dissemination in space incorporated in the McDonald 
International Panel criteria showed good specificity (89%). However, the 
more sensitive criteria proposed by a Subcommittee of the American 
Academy of Neurology resulted in a lower specificity (29%), indicating 
an increased risk of a false positive diagnosis. 
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Introduction:
In recent guidelines for diagnosing multiple sclerosis (MS) as proposed 
by the McDonald International Panel (IP)(McDonald et al. 121-27) 
magnetic resonance imaging (MRI) findings were given a critical role, 
mainly to allow for an earlier diagnosis of MS. MRI is the most sensitive 
paraclinical diagnostic test for MS (Gebarski et al. 469-74;Paty et al. 180-
85) but white matter abnormalities are known to be present in many other 
diseases as well. They have been reported in 40-95% of patients with 
other neurological diseases (Bot et al. 46-56;Offenbacher et al. 905-09) 
and even in 44% of elderly asymptomatic patients (Fazekas et al. 1822-
25).  
The MRI criteria as incorporated in the IP guidelines are based on 
a series of studies (Barkhof et al. 2059-69;Fazekas et al. 1822-25;Paty 
et al. 180-85;Tas et al. 259-64) in which the predictive value of different 
characteristics of white matter lesions for conversion from a clinically 
isolated syndrome (CIS) suggestive for MS to clinically definite MS 
(CDMS) according to previous criteria (the Poser criteria) was evaluated. 
Since their publication several studies (Dalton et al. 47-53;Tintore et al. 
27-30) have evaluated the IP guidelines and found a sensitivity of 74 
to 83%. The specificity in these studies was reported to be 83 to  85%. 
However, the relevance of the latter percentages may be questioned 
because all studies were performed in highly  selected patient groups. 
Patients were usually recruited in tertiary referral centres and had a 
typical presentation of CIS and a restricted age and disease duration. 
Moreover patients in whom (ultimately) another diagnosis was made, 
were typically excluded from analyses. Such populations are useful to 
address the issue of sensitivity but are of limited value to determine 
specificity. Because most patients from these selected populations have 
a second event over years (Brex et al. 158-64), these diagnostic criteria 
may be perceived as a parameter for disease prognosis rather than as 
an instrument  to diagnose difficult cases. 
A systematic analysis of studies resulted in a consensus report of 
the Therapeutics and Technology Assessment Subcommittee of the AAN 
(Frohman et al. 602-11) on the use of MRI in the diagnosis of MS. It 
was argued that three white matter lesions in patients with CIS represent 
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a more sensitive predictor of the subsequent development of CDMS, 
without affecting specificity. This assumes a population in which the prior 
chance of not having the disease is negligible, which is probably true for 
the populations in the published studies but may not be the case in a 
more general clinical setting.
To approximate the specificity of these two MRI criteria for 
dissemination in space in clinical practice, we studied a group of patients 
in whom their own neurologist suspected a diagnosis of MS but after 
second opinion another diagnosis was made. 
Patients and methods:
From the 754 consecutive cases referred to our MS Centre for a second 
opinion in the last 3 years before implementation of the IP criteria 
(between January 1998 and January 2001) the purpose of the referring 
neurologist was a confirmation or rejection of a suspected diagnosis of 
MS in 377 patients. In this group the following diagnoses were made 
using the Poser criteria for MS (Poser et al. 227-31): 195 definite MS 
(51.7%), 58 probable MS (15.4%), 5 other demyelinating disease (1.3%), 
29 other neurological diseases (OND; 7.7%), 3 both MS and another 
neurological disease (0.8%). In 87 (23%) cases no certain diagnosis 
could be made. In four cases essential parts of the medical files could 
not be retrieved. 
Of 29 OND patients 17 were diagnosed with ischemic cerebrovascular 
disease (ICVD), 4 with angiitis/vasculitis due to systemic inflammatory 
disease, 3 with multiple system atrophy and in 5 other single diagnoses 
were made. In order to determine ‘true’ specificity of diagnostic criteria 
we focused on patients in whom another diagnosis was positively 
made (OND). Patients in whom a diagnosis of MS could not (yet) be 
made were not included in the analysis to avoid circular reasoning and 
thus overestimating the specificity of the IP criteria. Diagnoses were 
always based on the combination of clinical, laboratory and (additional) 
radiological data, in a few patients including tissue biopsy, wherever 
possible in accordance with accepted diagnostic guidelines.
The original brain MRI on which the diagnosis of MS was suspected 
was available for 28 of these 29 patients. To mask the radiologist for 
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the ultimate diagnosis we mixed these scans with 28 scans of randomly 
selected patients from the same cohort in whom the diagnosis of definite 
MS according to the Poser criteria was confirmed. Thus, 56 patients were 
included in the analysis. The scans were presented in random order to 
an experienced neuroradiologist who scored the scans according to the 
MRI characteristics as incorporated in the different diagnostic criteria 
that then were specified as either fulfilling or not fulfilling the criteria 
for dissemination in space as incorporated in the IP guidelines and the 
criterion of three or more lesions as proposed by the AAN Subcommittee.
Specificity (true-negative rate) and sensitivity (true-positive rate) 
and 95% confidence intervals (CIs) were calculated for both the IP MRI 
criteria and the AAN criterion using CIA software (version 2.0.0 Trevor 
Bryant, University of Southampton). Additional statistical tests were 
performed using SPSS software (version 11.0). Reported p values are 
based on two-tailed significance tests with a threshold of 0.05.
Results:
Patient characteristics are summarized in Table 1. Patients with OND 
were older than MS patients (p=0.002), but had comparable sex 
distribution and disease duration. Imaging characteristics and univariate 
OR for different MRI characteristics are displayed in Table 2. 
Table 1. Patient characteristics
Patient characteristics Other neurological diseases (N=28) MS (N=28)
Age* 49.8 (SD 9.5) 41.6 (SD 8.7) 
Gender** (female: male) 17:11 20:8            
Disease duration*** 2.6  (3.7) years 1.9 (2.6) years
Type of MS 20 (71.4%) RR****
 5 (17.9%)  PP****
 3 (10.7%)  SP****
*mean value and standard deviation; difference significant (p=0.002).
** difference not significant
*** median and interquartile range; difference not significant
****(Lublin and Reingold 907-11)
CHAPTER 2
30 Three of the 28 OND patients fulfilled the IP MRI criteria. These 
patients (one case of vasculitis and two of ICVD) all had more than 35 
T2 lesions. By contrast, 20 OND patients fulfilled the AAN criterion. This 
results in a specificity of 89% (95% CI: 73-96%) for the IP MRI criteria 
and 29% (95% CI: 15-47%) for the AAN criterion (Table 3). The sensitivity 
in the random sample of 28 MS patients was 64% (95% CI 46-82%) and 
93% (95% CI 77-98%) respectively.
Discussion:
We addressed the utility of different MRI criteria for MS for the first time 
in a sample where diagnostically difficult cases are over represented 
rather than excluded. The specificity of diagnostic criteria in clinical 
practice is more reliably estimated using such a population compared to 
a population in which all other diagnoses are excluded. 
Table 2. MRI characteristics
Imaging findings OND (n=28) MS (n=28) Odds ratios MS vs 
OND (95%CI)
≥ 9 T2 lesions 14 (50%) 22 (79%) 3.7 (1.1-11.8)
Infratentorial lesion present 7 (25%) 18 (64%) 5.4 (1.7-17.1)
Juxtacortical lesion present 4 (14%) 15 (54%) 6.9 (1.9-25.2)
3 periventricular lesions present 5 (18%) 21 (75%) 13.8 (3.8-50.2)
≥ 3 T2 lesions 20 (71%) 26 (93%) 5.2 (1-27.2)
OND = other neurological disease, CI = confidence interval
Table 3. MRI scans accomplishing the different MRI criteria and their diagnostic properties.
OND (n=28) Specificity (CI) MS (n=28) Sensitivity (CI)
IP MRI criteria positive 3 (11%) 89% (73-96) 18 (64%) 64% (46-82)
AAN criterion positive 20 (71%) 29% (15-47) 26 (93%) 93%(77-98)
OND = other neurological disease, IP = International Panel, AAN = American Academy of 
Neurology, CI = confidence interval
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Ideally such a study would be carried out prospectively; however, 
as the IP criteria have become a worldwide standard for the diagnostic 
process for MS, this remains a difficult task. Furthermore, we tried to 
optimise generalizability by selecting all patients referred by a neurologist 
for a second opinion regarding a possible diagnosis of MS, without any 
restrictions on age, typical presentation or maximum disease duration, 
even though the referral to a specialised MS centre does involve referrals 
of unusual cases and possibly to some extent cases that were not yet 
completely evaluated before referral.
The difference in age between the OND and the MS group expresses 
the average older age of onset of ICVD,  neurodegenerative disease 
and age-related white matter changes as opposed to MS. However, 
although distinctive at a group level, this showed not to be valuable for an 
individual patient as illustrated by the large overlap between the groups.
The sensitivity of the IP MRI guidelines in this study (64%) was 
comparable to sensitivities of 69% and 71% reported before in CIS 
patients (Dalton et al. 47-53;Tintore et al. 702-06). The AAN criterion 
indeed had a higher sensitivity (93%), which is especially valuable to 
prevent false negative diagnosis. However, for the confirmation of 
the diagnosis, a test with a high specificity is needed. In the studies 
performed so far, specificity was defined in relation to risk for conversion 
to clinically definite MS rather than to misdiagnosis. In this study, the 
specificity of the IP MRI criteria was shown to be higher compared with 
the AAN criterion. This is probably driven by criteria for location of lesions 
rather than number of lesions.
After initial screening for alternative diagnoses as performed by 
the referring neurologist, the AAN criterion would have allowed for 20 
(5.3%) incorrect MS diagnoses in a group of 377 patients as opposed 
to 3 (0.8%) when applying the IP MRI guidelines. This observation is of 
increasing importance in an era where an early diagnosis of MS is more 
and more likely to lead to early initiation of disease-modifying treatment, 
which is both expensive and associated with side effects.
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With great interest we read Drs Goodin and Frohman’s response (1) to 
our article (2). 
We agree that determining the true cost-benefit of different diagnostic 
strategies is complicated. In our judgment, which indeed might be 
simplistic, we prefer high specificity to high sensitivity because the 
impact of a potentially life-long false-positive diagnosis might be greater 
than that of postponing disease modifying therapy [DMT] -for which long-
term effects have only incompletely been assessed- until a next attack. 
It seems likely that the diagnosis of multiple sclerosis (MS) would rather 
have been delayed than actually prevented, as suggested by Goodin and 
Frohman,  in 25.5% of the cases if these would have relapsing disease 
and qualify for treatment with disease modifying therapy. 
We fully agree with the authors that our sample is not representative 
of typical MS patients in general. As we stated in our article (2), it 
concerns cases that were referred for a second opinion, a sample where 
diagnostically difficult cases are over-represented rather than excluded. 
It is precisely this group, where the differentiation with other MS-like 
diseases is so important and difficult and where specific magnetic 
resonance imaging (MRI) guidelines can be of extra value. We do not 
know whether these patients were mainly referred because of their MRI 
or because of their clinical presentation; we can only state that they were 
referred by certified neurologists because of a diagnosis of MS being 
seriously considered, ‘a real life’ situation.
As we acknowledged in our article (2), indeed, the design of a study 
such as the one we performed, should ideally be prospective. Goodin 
and Frohman do not share our belief that such a study would be difficult 
to perform. Awaiting the results of this important prospective research, 
we believe that our data do provide guidance on some features of the 
proposed diagnostic strategies.
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Abstract: 
New diagnostic criteria for Multiple Sclerosis have been proposed by 
Swanton and coauthors, but were not yet evaluated in patients suspected 
of MS, but diagnosed with another disease. The dissemination in space 
criterion of these Swanton criteria was investigated in such a patient 
group and compared to the present McDonald criteria. We found that 
with the Swanton criteria for DIS, simplicity can be combined with some 
gain in sensitivity, without major loss of specificity.
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Introduction: 
Current diagnostic guidelines for multiple sclerosis (MS) (McDonald et 
al. 121-27;Polman et al. 840-46) partly rely on MRI criteria that were 
proven to be sensitive and specific (Dalton et al. 47-53;Korteweg et al. 
221-27;Nielsen et al. 781-83) in their ability to predict a second clinical 
episode and thus antedate the diagnosis of MS according to the former 
Poser criteria (Poser et al. 227-31). Unfortunately, these McDonald criteria 
have high complexity (McDonald et al. 121-27;Polman et al. 840-46), and 
recently simplified MRI criteria have been proposed by Swanton (Swanton 
et al. 730-3). Compared to the McDonald criteria, two major changes 
were incorporated. First, fewer T2 lesions are required; dissemination in 
space (DIS) can be fulfilled by the presence of T2 lesions in at least two 
of four locations. Second, a new T2 lesion at any time provides evidence 
for dissemination in time (DIT), a requirement more sensitive than a 
gadolinium enhancing lesion as requirement for DIT (Dalton et al. 673-
76). Compared to the Mc Donald criteria, these changes seem to improve 
the sensitivity, without compromising specificity - which was reported to 
be 87% in a multicenter study (Swanton et al. 677-86). However, the 
relevance of this observed specificity can be questioned. The studied 
patient population comes from several tertiary referral centers and before 
inclusion other diagnoses have been excluded. Thus, high specificity in 
this study concerns patients who do not fulfill the criteria nor experience 
a second episode of MS symptoms during the follow up. This specificity 
is thus merely related to disease progression rather than a property of 
the criteria to differentiate MS from other diseases.  
To investigate diagnostic performance in clinical practice, we studied the 
present (revised) McDonald (McDonald et al. 121-27;Polman et al. 840-
46) and the newly proposed Swanton MRI criteria(Swanton et al.) for 
DIS in a patient population (Nielsen et al. 781-83) that was referred for 
suspected MS by their own neurologist, but in whom another diagnosis 
was made after a second opinion. This population was previously used 
to compare diagnostic sensitivity and especially specificity (Nielsen et al. 
781-83), comparing the McDonald criteria with the criteria proposed by 
the AAN (Frohman et al. 602-11). 
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Patients and methods: 
The study population has been described elsewhere in more detail 
(Nielsen et al. 781-83). Briefly, out of all consecutive 377 patients 
referred for a second opinion between 1998 and 2001, 28 patients were 
diagnosed with other neurological diseases (OND): 17 with ischemic 
cerebrovascular disease, four with angiitis/vasculitis, three with multiple 
system atrophy and five with single other diagnoses.  These and 28 
recently diagnosed MS patients randomly selected from the same 
population were studied.  Brain MRI characteristics of these patients 
were specified as either fulfilling or not fulfilling the criteria for DIS as 
incorporated in the McDonald guidelines and as proposed by Swanton 
et. al. Specificity (true negative rates) and sensitivity (true positive rates) 
and 95% confidence intervals (CIs) were calculated for both the (revised) 
McDonald criteria and the Swanton criteria using CIA software (version 
2.1.2, Trevor Bryant, University of Southhampton). Comparisons of 
patient characteristics between groups were performed using SPSS 
software (version 16.0). Reported p values are based on two-tailed 
significance tests.
Results: 
OND patients were older than MS patients (p=0.002) but had comparable 
gender distribution and disease duration5. We found no difference 
in either the OND nor the MS patient groups fulfilling the original 
McDonald(McDonald et al. 121-27) or the revised McDonald(Polman et 
al. 840-46) criteria, thus the patient characteristics of these groups are 
reported as one (Table 1). Four OND patients fulfilled the Swanton criteria 
for DIS, whereas three patients fulfilled the (revised) McDonald criteria. 
This results in a specificity of 86% (95% CI, 69 - 94%) for the Swanton 
and 89% (95% CI, 73 - 96%) for the (revised) McDonald MRI criteria. 
The patient that did fulfill the Swanton, but not the McDonald criteria 
had 6 T2 lesions. She was diagnosed with neurological complications 
of celiac disease . In this sample of MS patients the sensitivity for the 
McDonald criteria was 64% (95% CI, 46 - 79%), for the Swanton criteria 
71% (95% CI, 53 - 85%). This was due to two patients who did not fulfill 
the McDonald, but did fulfill the Swanton criteria.
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Table 1. MRI scans that accomplish the different MRI criteria and their Diagnostic properties. 
Diagnostic Criteria OND (n=28) Specificity (CI) MS (n=28) Sensitivity (CI)
Swanton DIS 4 (14%) 86 (69 – 94) 20 (71%) 71 (53 – 85)
2005 McD-DIS 3 (11%) 89 (73 – 96) 18 (64%) 64 (46 – 79)
OND= other neurological disease, DIS=dissemination in space, CI=confidence interval, 
McD = Mc Donald criteria 
Discussion: 
This is the first study comparing specificity and sensitivity of the 
Swanton criteria for DIS with the McDonald criteria in a population in 
which diagnostically difficult cases are overrepresented rather than 
excluded. To optimize generalizability, we included all patients referred 
by neurologists concerning a possible MS diagnosis irrespective of age, 
symptoms or disease duration, even though this does involve referrals 
of unusual cases and possibly to some extent cases that were not yet 
completely evaluated before referral. 
The older age of the OND group versus the MS group expresses 
the average older age of onset of ischemic cerebrovascular disease, 
the main differential diagnosis. We found the diagnostic performance of 
the McDonald criteria and the Swanton criteria to be very similar in the 
population studied in this paper. There was only one OND patient who 
was diagnosed as MS with the Swanton criteria and not the McDonald 
criteria (specificity 86% versus 89%) and there were 2 MS patients who 
were diagnosed with the Swanton criteria and not the McDonald criteria 
(sensitivity 71% versus 64%). The sensitivity of the Swanton criteria in 
our study is lower than reported previously (90% and 85.9% [95% CI 
76.5-92.5])(Swanton et al.; Swanton et al. 677-86). This might be due to 
the primary progressive patients in the MS group, as these are known to 
have fewer cerebral lesions compared with relapsing-remitting patients. 
There are several limitations to our study: first we studied only 
DIS and not DIT. With the simplification of the DIS criteria, it should 
be remembered that DIT is an important requirement to diagnose MS 
and thus ensure high specificity. Diagnosing MS without fulfilling the 
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DIT requirement should be discouraged. Furthermore this study should 
ideally be carried out prospectively instead of retrospectively as was 
done in this study. However, this remains a difficult task as the McDonald 
criteria are standard and there is presently no accepted alternative.
Previously, using exactly the same patient sample, we showed 
that diagnostic criteria proposed by the AAN behaved sub optimally 
because simplicity and increased sensitivity came at the price of much 
lower specificity. Here we show that with the Swanton criteria for DIS, 
simplicity can be combined with some gain in sensitivity, without major 
loss of specificity. Ideally our observation should be confirmed in a larger, 
prospectively collected sample, evaluating not only DIS, but also DIT. In 
the absence of such sample this study provides some assurance of the 
diagnostic behavior of the Swanton criteria in a sample which consists of 
diagnostically difficult cases. 
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Abstract
Objective  There is no gold standard diagnostic test for MS, and 
evaluation of present diagnostic guidelines has almost exclusively been 
done in populations of which the vast majority is prone to develop MS. 
Patients referred for a potential MS diagnosis in whom ultimately another 
or no diagnosis is made are seldom reported in a systematic way. We 
report, after 7 years, on the diagnoses made in a cohort of patients with 
suspected though unconfirmed MS.
Methods  We retrieved information on the current diagnosis of all patients 
who had visited our centre  between 1998 and 2001 for a second opinion 
concerning a possible MS diagnosis and in whom no diagnosis had been 
made at that time. 
Results  Seventy-five patients (86%) could be retrieved and cooperated. 
In seven patients, a diagnosis of MS, in eight patients another 
neurological diagnosis had been made. In the remaining 60 patients, still 
no neurological diagnosis had been made.
Conclusions  In potential MS patients seen in a tertiary referral centre, 
the likelihood that a patient who is not diagnosed with MS will in the 
future develop a neurological disease is small. This study suggests that, 
in addition to playing a role in diagnosing MS, MRI can be helpful to 
exclude MS in clinically doubtful cases.
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Introduction
In the past decades, the process of diagnosing MS has fundamentally 
changed, largely because of the incorporation of (more detailed) MRI 
criteria in the consecutive versions of diagnostic guidelines (Poser et 
al. 227-31;McDonald et al. 121-27;Polman et al. 840-46). Nevertheless, 
a ‘gold standard’ diagnostic test is still lacking and evaluation of the 
diagnostic guidelines has almost exclusively been done in populations 
of which the vast majority of patients is likely to develop MS (Brex et 
al. 158-64). Patients referred for a potential MS diagnosis in whom 
ultimately another or no diagnosis is made are seldom reported in a 
systematic way. Previously, we reported on a group of such patients 
in whom another diagnosis was made short after initial referral for MS 
(Nielsen et al. 781-83). We now report on the follow up of patients from 
the same cohort in whom initially no certain diagnosis was made in our 
MS Centre, a tertiary referral centre. In this group we retrieved additional 
diagnostic information, 7 years after we had initially seen the patient, to 
be able to analyse diagnostic errors and potentially identify red flags in 
order to improve the diagnostic process in future cases.
Patients & methods:
We retrieved medical charts of all cases referred to our MS Centre 
for a second opinion between January 1998 and January 2001; 377 
patients were referred for diagnostic purposes with the referring certified 
neurologist considering an MS diagnosis. Diagnoses made in these 
patients have been described before (Nielsen et al. 781-83). In 87 (23 
%) patients (mean age 42 yrs; 47 women) no diagnosis could be made 
at the time of referral. In 2006, these 87 patients were asked to consent 
to an interview by phone regarding their present medical condition and 
diagnosis. If a diagnosis had been made in the interval period, additional 
visits to a neurologist or another relevant specialist were reported or the 
patient reported to have worsened, the patient’s consent was requested 
to obtain further information from the general practitioner, neurologist 
and/or other specialist. The study received approval from the medical 
ethics committee of the VU Medical Center. 
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Results:
In 75 out of 87 (86%) cases, the patient or authorized relation consented 
and was interviewed by phone. Twelve patients (10 women) refused or 
could not be retrieved. Baseline characteristics of these patients were 
similar to those of the rest of the group. A flow chart of patients is depicted 
in figure 1. 
Figure 1 Flow chart of patients referred for suspected MS by a neurologist from 1998 until 
2001
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In seven (9%) patients (six women) a diagnosis of  MS had been 
made after 7 years on a combination of clinical course and MRI 
abnormalities. 
In eight cases (11 %, 6 women) another neurological disease (OND) 
had been diagnosed;
 - In four patients cerebrovascular disease: on follow-up these patients 
experienced new vascular events and/or had additional investigations, 
cq (casu quo; as the case may be) in one patient a post mortem was 
performed. In these patients we had initially rejected the diagnosis 
MS because of brain MRI and/or clinical presentation being atypical 
for MS, in the absence of clear evidence for vascular disease.
 - Single cases of ALS, hereditary spastic paraplegia and anterior horn 
cell disease: the first two both presented with a slowly progressive 
paraparesis but MS was rejected because of normal spinal cord MRI 
findings.
 - A single case of narcolepsy who seven years before had presented 
with fatigue and intermittent weakness of the left leg, which was 
found atypical for MS, also because both spinal and brain MRI were 
normal. 
In 60 (80%) patients (47 women) still no diagnosis had been made. 
Additional medical information was received from 40 of these patients. 
Twenty-eight patients had again visited a neurologist. Three patients 
had died because of: a cardiac arrest, an unknown neurological disease 
and suicide. The median follow-up duration of the remaining 57 patients 
was seven years. Of  57 patients 23 (40 %) had recovered from their 
presenting symptoms at the time of follow up, in 26 (46%) patients there 
had been no change in symptoms,  8 (14%) patients reported to have 
worsened. 
Discussion
In the vast majority (80%) of patients who were referred because of 
suspected demyelinating disease, but in whom no definite diagnosis 
could be made at the time of referral, no neurological diagnosis was 
made during an average follow-up of seven years. In 20% of these 
patients (i.e. only 4% (n=15) of the original total cohort of 355 patients) 
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a diagnosis was eventually made. MS was diagnosed in seven and 
another neurological disease in eight patients. In most patients in whom 
ultimately another neurological diagnosis was made, it was found that 
at initial presentation a diagnosis of MS had been rejected because of 
MRI findings: brain lesions were atypical for MS or spinal cord MRI was 
normal where clinical presentation suggested spinal cord involvement. 
Specific symptoms or signs pointing to the disease that was ultimately 
diagnosed were not present or not recognized.
Inability to make a final diagnosis in patients referred to a tertiary 
centre for suspected MS is a well-known problem. To our knowledge, 
this is one of the first studies to address this issue by performing a 
systematic long-term follow-up of such patients. Our population is clearly 
different from that seen in a general neurology clinic and biased towards 
diagnostic uncertainty. However, we have no indication of any other bias. 
Given the long interval between referral and this study, the number of 
patients lost to follow-up is acceptable. Furthermore, we don’t think that 
with this approach – initially by phone, thereafter requesting information 
from medical doctors – we missed many important diagnoses, even 
though we cannot be certain.
The main conclusion is that in potential MS patients seen in a tertiary 
MS referral centre, the likelihood that a patient who is not diagnosed with 
MS will in the future develop a neurological disease is small. Whereas 
current diagnostic criteria emphasize the role of MRI in diagnosing MS, 
this study points to the role of MRI in  excluding MS in clinically doubtful 
cases.
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Summary
Background A 29-year-old male presented with fluctuating but progres-
sive sensory disturbances comprising tingling and dysesthesia in his 
right leg. MRI of the brain showed white matter lesions initially thought to 
be caused by multiple sclerosis. 
Investigations Neurological examination, cerebrospinal fluid examina-
tion, laboratory blood testing, brain and spinal MRI scans.
Diagnosis Spinal cord schwannoma.
Treatment and Management  Surgical removal of the schwannoma. An 
algorithm is provided that clarifies the appropriate MRI work-up for cases 
where the clinical presentation is suggestive of multiple sclerosis.
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The case
A 29-year-old man presented to the neurology department of a local 
hospital with an 18 month history of fluctuating sensory disturbances 
consisting of tingling and DYSESTHESIA in the right leg. The symptoms 
had initially been limited to the right foot, but approximately 1 year before 
his presentation, they had worsened and ascended to the right knee and 
later to the entire right leg. The patient also complained about a general 
feeling of stiffness, slight balance problems and falling more easily. He 
had noticed increased fatigue, especially when walking long distances. 
He had not noticed any muscle weakness, and his bladder function was 
normal. His medical history was unremarkable, and revealed no other 
neurological problems. Neurological examination was normal, apart from 
brisk muscle tendon reflexes in all four extremities. Laboratory testing 
for hematology, renal function, glucose, thyroid function and vitamin 
B12 was normal. Borrelia antibody and treponemal hemagglutination 
(TPHA) testing was negative in the serum as well as in the cerebrospinal 
fluid (CSF). CSF testing also showed normal electrophoresis with no 
oligoclonal bands and a normal IgG index, but a slightly increased total 
protein level (0.67 g/l). An MRI scan of the brain showed several white 
matter lesions, some of which were located close to the cerebral ventricles 
(Figure 1). On the basis of these findings, the patient was diagnosed with 
multiple sclerosis (MS) and was referred to an MS Center for a second 
opinion, including a therapy consultation.
 
Approximately 2 months passed after the diagnosis before the patient 
was seen at the MS clinic. On presentation, his symptoms had 
worsened—walking had become more problematic, and he reported an 
altered sensory function while urinating, although his bladder control was 
still normal. On neurological examination, no major walking problems 
were observed. Detailed testing of motor function revealed a slight loss 
of strength in the left leg. The patient’s abdominal reflexes were absent, 
and he had very brisk reflexes in the legs and bilateral extensor plantar 
reflexes. There was a decreased pinprick discrimination descending 
from thoracic level 10 (T10) and vibration sense was abnormal in both 
legs. Testing of his coordination revealed a minimal intention tremor of 
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the right hand. Otherwise, examination of his upper extremities, cranial 
nerves and cognitive function was normal.  
Because the current presentation was one of a slowly evolving spinal 
cord syndrome, MRI scanning was repeated, this time to also include the 
spinal cord (Figure 2). This revealed an intraspinal hypointense lesion 
at the level of T4–5, which enhanced after intravenous administration 
of a contrast agent. The lesion was surrounded by edema and had a 
compressing effect on the cord tissue. A diagnosis of an intraspinal tumor 
was made and the patient was referred for neurosurgical intervention. 
The tumor was surgically removed and microscopic examination showed 
it to be a schwannoma. The postoperative course was uneventful and in 
the following months the patient fully recovered, apart from a focal area 
of HYPESTHESIA on his trunk that had most probably resulted from the 
T5 nerve origin of the tumor. 
Discussion of diagnosis
MS is among the most common causes of disability in young adults in 
Western countries, with a disease prevalence of approximately 1 per 
1000 in Caucasians. However, establishing a diagnosis of MS requires 
careful consideration.  Fluctuating sensory disturbances and discrete 
motor abnormalities in a young patient are a fairly common presentation 
of MS. Ever since the disease was first described, doctors have faced 
difficulties in determining whether an individual with certain neurological 
signs and symptoms actually has MS, because there is no single 
definitive diagnostic test available for the disease. Traditionally, the 
diagnostic process has involved obtaining evidence from the patient’s 
history, clinical examination and a variety of laboratory tests, all intended 
to gather data consistent with a diagnosis of MS and to rule out other 
possible causes of disease (Poser et al. 227-31;Schumacher GA et al. 
552-68). 
MRI investigations have become important in helping to confirm a 
diagnosis of MS, but it was not until 2001 that an international panel 
for the diagnosis of MS presented new diagnostic criteria known as the 
McDonald criteria, which focused specifically on the use of MRI as an aid 
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to diagnosis (McDonald et al. 121-27). Although the McDonald criteria 
stipulate that the core of an MS diagnosis is the demonstration at physical 
examination of typical disease symptoms and signs disseminated in 
time and space, they were the first to provide a detailed description of 
how MRI can be used to demonstrate abnormalities consistent with MS, 
with respect to dissemination in both time and space. Revisions to the 
McDonald criteria were recommended in 2005, both to incorporate new 
research findings and to clarify issues that could easily be misinterpreted.
Figure 1. T2 - weighted transverse image of the brain showing multiple high-signal lesions 
around the ventricles.
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Figure 2. Spinal cord MRI revealing 
an intradural hypointense (probably 
calcified) mass on T2-weighted images. 
(A) with surrounding edema (high signal) 
in the compressed cord. After contrast 
administration, the mass enhances and is 
better delineated on sagittal (B) and axial (C) 
T1-weighted images.
Figure 2b
Figure 2a
Figure 2c 
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(Polman et al. 840-46) These revisions relate to the guidelines for the use 
of MRI to demonstrate dissemination of disease in time, the question of 
how spinal cord MRI findings should be taken into account in this context, 
and the criteria required to achieve a diagnosis of primary progressive 
MS. Even though the MRI criteria have been selected because they have 
a relatively high specificity both the original publication and the recent 
revision stress the importance of eliminating alternative conditions that 
might ‘mimic’ MS. 
The MRI criteria to demonstrate brain abnormality and dissemination 
in space are based on the Tintoré adaptation of the criteria initially 
provided by Barkhof et al. (Barkhof et al. 2059-69;Tintore et al. 702-
06) For these characteristics to be demonstrated, three out of four of 
the following criteria should be fulfilled on the brain MRI: at least one 
gadolinium enhancing lesion or nine hyperintense lesions on T2-
weighted MRI if there is no gadolinium enhancing lesion; at least one 
infratentorial or spinal cord lesion; at least one juxtacortical lesion; at 
least three periventricular lesions. One spinal cord lesion can substitute 
for one brain lesion.
The presenting symptoms of the patient in this case were mild, abnormal 
findings at neurological examination. These were not recognized as 
representing a spinal cord syndrome, and a spinal cord MRI was therefore 
not performed at the initial stage. Not only was the neuroanatomical 
interpretation of symptoms and signs at that time inappropriate, but so 
was the interpretation of the time course of the symptoms. A first episode 
of MS in a young adult typically presents as a so-called ‘clinically isolated 
syndrome’ of neurological dysfunction of the type commonly seen in MS 
(i.e. optic neuritis, incomplete spinal cord syndrome), with a relatively 
sudden onset (within days), a plateau phase, and at least partial 
recovery over weeks to months. The patient described here presented 
with fluctuating but slowly progressive abnormalities, rather than with a 
discrete relapse (deterioration–plateau–recovery). Certainly, a so-called 
‘primary progressive’ disease course does occur in a percentage of MS 
patients (5-10%), but patients with this disease subtype are typically in 
their forties or fifties. Moreover, spinal cord MRI is of great diagnostic 
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relevance—particularly in cases of primary progressive MS—and it is a 
requirement that this be undertaken in patients presenting with a spinal 
cord syndrome, irrespective of the suspected underlying disease.
The diagnosis of MS in the present patient was based heavily on the 
interpretation of the results of his MRI brain scan. On critical review of the 
scan, there were approximately 10 small lesions distributed throughout 
the brain white matter, 3 of which were in a periventricular location. In the 
absence of juxtacortical or infratentorial lesions, only two out of four of the 
Tintore/Barkhof criteria were fulfilled - insufficient to prove dissemination 
in space according to the McDonald criteria. In addition, the results of 
the CSF examination should have provided an alert - not only were 
signs of intrathecal IgG synthesis lacking (the IgG index was normal 
and oligoclonal bands were absent), but there was also an elevated total 
protein concentration, which is atypical of MS.
 
A spinal cord MRI scan enabled the correct diagnosis to be achieved in 
the present case. In addition to providing either proof of or evidence to 
rule out an alternative diagnosis, spinal cord MRI scans often provide 
positive evidence of MS. Dual-echo spin-echo MRI is most sensitive for 
the detection of spinal cord abnormalities, which range from focal lesions 
to signal intensity with greater diffusion, the latter being more frequently 
observed in (primary) progressive MS (Lycklama et al. 555-62). In 
a diagnostic setting, spinal cord imaging is valuable for two reasons. 
First, the presence of asymptomatic spinal lesions can help confirm a 
diagnosis of MS in cases where there are few brain lesions present,(Bot 
et al. 226-33) although it should be noted that in patients with very few or 
only one lesion—as is seen for example in a number of patients with optic 
neuritis—there is no extra value in performing a spinal cord MRI scan 
because the presence of an additional typical spinal cord lesion would 
still not fulfill the McDonald criteria. Second, because asymptomatic 
spinal cord lesions are rare in disorders other than MS, in a patient with 
equivocal brain findings such as an elderly patient with ischemic vascular 
lesions and a prolonged disease duration, a normal spinal cord MRI scan 
can help rule out MS (Bot et al. 46-56). 
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Table 1 presents an algorithm for the appropriate MRI diagnostic work-
up in cases where the clinical presentation is suggestive of MS: this 
algorithm is proposed to support, rather than replace, clinical decision 
making. On the basis of the algorithm, the patient presented in this case 
should have undergone spinal cord MRI, irrespective of whether the 
clinical presentation was interpreted as being a spinal cord syndrome. 
Differential diagnosis
Brain white matter lesions are most frequently seen in normal aging 
and in cerebrovascular disease, but they are also prevalent in  up to 
10 % of asymptomatic younger adults (Fazekas 164-68). In addition to 
normal aging and cerebrovascular disease, the differential diagnosis for 
brain white matter lesions includes systemic inflammatory disease (for 
example lupus erythematosus or sarcoidosis), brain infection such as 
neuroborreliosis, and migraine (Fazekas 164-68). In some patients, it 
Table 1 Algorithm for an MRI work-up in cases where the clinical presentation is suggestive 
of multiple sclerosis, either as a first episode or as a slow progression.
Presentation Recommended
procedure
Reasons for procedure Next steps
Spinal cord
presentation
Spinal cord MRI ■ To exclude alternative 
lesions such as spinal cord 
compression
■ To demonstrate  
multiple-sclerosis-like 
abnormalities
■ Brain MRI recommended if 
multiple sclerosis is suspected, to 
demonstrate (further) dissemination 
in space
■ Consider follow-up brain MRI at 
3 months, 12 months, or both to 
demonstrate dissemination in time
Non-spinal-
cord
presentation
(i.e. brain or
optic nerve
presentation)
Brain MRI ■ To demonstrate  
multiple-sclerosis-like 
dissemination in space
■ To exclude an alternative 
diagnosis
■ Spinal cord MRI recommended 
if multiple sclerosis is suspected, 
(only) if brain MRI is inconclusive 
(e.g. multiple white matter lesions in 
a hypertensive patient) or if criteria 
for dissemination in space are not 
met on brain MRI
■ Consider follow-up brain MRI at 
3 months, 12 months, or both to 
demonstrate dissemination in time
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is not possible to identify a specific cause for the lesions, even after 
extensive diagnostic investigation. In such cases, the lesions are more 
likely to be of a vascular nature than to be caused by MS. It is advisable, 
therefore, to apply stringent—rather than lenient—MRI criteria for MS, 
particularly in an atypical clinical setting.
Conclusion
The patient in the present case was initially misdiagnosed with MS, 
thereby inducing a therapeutic delay of several months that could have 
been prevented if adequate imaging had been carried out after his initial 
presentation.  This case illustrates that in order to achieve a correct 
diagnosis in patients presenting with symptoms similar to those seen 
in the present patient, a careful interpretation of medical history and 
signs at the time of physical examination is essential. The proposed MRI 
algorithm ensures that appropriate imaging procedures are undertaken. 
White matter lesions - even when consistent with a diagnosis of MS - 
should be interpreted with care, and appropriate application of the 
McDonald criteria can help to distinguish MS from other conditions.  
Glossary
DYSESTHESIA An unpleasant abnormal sensation, which can be 
spontaneous or evoked 
HYPESTHESIA A decreased tactile sensitivity
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Abstract:
Background: Recently, a clinical classification system was described 
to determine whether symptoms and signs of patients presenting with a 
first episode suggestive of multiple sclerosis (MS) indicate the presence 
of monofocal or multifocal disease. 
Objectives: To evaluate the value of this new classification system by 
comparing the results with those of simultaneously obtained magnetic 
resonance imaging (MRI) scans.  
Methods: The 487 patients randomised in the BENEFIT study were 
centrally assessed using the new system and classified as monofocal 
or multifocal based on clinical information by two neurologists, masked 
for the MRI results. MRI analyses were performed by expert readers 
masked for the clinical classification. 
Results: Patients classified as ‘multifocal’ had more T2 hyperintense 
(median 21 versus 15.5) and more T1 hypointense lesions (median 2 
versus 1) than those classified as ‘monofocal’. Patients classified at the 
local site as having evidence of a single clinical lesion, but reclassified 
centrally as having a clinical multifocal central nervous system 
presentation, had more T2 lesions than monofocal patients. In addition, 
patients with a multifocal presentation more often fulfilled the MRI criteria 
for dissemination in space as incorporated in the International Panel (IP) 
diagnostic criteria for MS.
Conclusion: These data provide justification for the recently proposed 
clinical classification system to be used in patients who present with a 
first episode suggestive of MS in that ‘multifocal’ based on symptoms 
and signs is associated with more lesions on MRI. 
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Introduction:
A diagnosis of MS requires evidence for dissemination in space and time 
of lesions in the central nervous system (Schumacher GA et al. 552-
68). In providing this, clinical data are essential but additional evidence 
from paraclinical examinations can also be used. According to the most 
recent diagnostic criteria for MS, as recommended by the International 
Panel (IP) for the diagnosis of MS, the amount and type of additional 
MRI data needed for a diagnosis depend on the clinical presentation, 
more specifically on whether clinical evidence of one or more suspected 
anatomical lesions in combination with one or two episodes is already 
provided (McDonald et al. 121-27;Polman et al. 840-46). This clinical 
evidence is based upon symptoms and signs resulting from the history 
and neurological examination of the patient. Whether these can best 
be explained by one or by more underlying anatomical lesions, and, 
thus provide, evidence for dissemination in space, is left to the clinical 
judgment of the physician. Whereas the IP criteria provide detailed rules 
for dissemination in space based on MRI, no guidance is provided on how 
to integrate clinical findings. Since this can lead to substantial variability 
between physicians, a strategy for a uniform approach is imperative. This 
is especially true with respect to the terminology ‘ monosymptomatic’ 
vs. ‘polysymptomatic’, thought to result from respectively, a single lesion 
and more lesions in the central nervous system (CNS). It was realized 
however, that ‘monosymptomatic’ patients can have examination findings 
indicating silent lesions elsewhere in the CNS and that a single lesion 
(e.g. brainstem) can result in a ‘polysymptomatic’ clinical presentation.
Recently, a classification system for the interpretation of clinical 
findings was proposed, which aims to translate signs and symptoms 
into underlying lesions in a standardized way (Uitdehaag et al. 227-
31). This system leads to the classification of patients who present with 
clinically isolated syndromes (CIS) as monofocal or multifocal disease 
presentation. It was first applied centrally in the BENEFIT study. The 
results showed differences in the interpretation of the local investigator 
and the centrally applied classification system in 81 out of the 496 
patients evaluated (16%) with respect to the presumed presence of one 
or more lesions, based on clinical findings (Uitdehaag et al. 227-31). 
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Reclassification to multifocal was most common, usually based on extra 
signs observed at neurological examination. A typical example is a patient 
who presents with an optic neuritis in whom at physical examination 
signs of pyramidal tract involvement are found based on the presence 
of a Babinski’s sign. This kind of patient was often classified by the local 
investigator as monofocal, but reclassified as multifocal while using the 
classification system.
Lesions on MRI consistent with demyelination are the best in vivo 
biological marker of MS. MRI is the most sensitive measurement to show 
the presence of multiple lesions. Moreover, follow up studies have shown 
that in CIS patients the number of T2 hyperintense lesions correlate, 
although moderately, with future disease course (Brex et al. 158-64).
To evaluate the value of the newly proposed clinical classification 
system, we compared the results with MRI scans performed at the same 
time. We hypothesised that CIS patients who were clinically classified 
as multifocal had more MRI abnormalities than monofocal patients and 
that multifocal CIS patients were more likely to fulfil the MRI criteria for 
dissemination in space as incorporated in the IP criteria. In addition, 
we evaluated whether the reclassified cases were justified by the MRI 
findings.
Patients and methods: 
All patients in this study were participants in the BENEFIT study, which 
compares high dose high frequency interferon beta-1b to placebo. 
(Kappos L. et al. 1242-49) In this study the systematic classification 
scheme was applied to 496 patients. Eventually 487 patients were 
randomized in the study and of all these patients quantitative MRI data 
were available. Main inclusion criteria were: age between 18 and 45; 
single, first clinical episode suggestive of demyelinating disease within 
the last 60 days; at least two clinically silent lesions on T2 weighted 
brain MRI, at least 3 mm in size, one of which should be ovoid, 
periventricular or infratentorial. As MS according to the IP criteria was 
one of the primary endpoints for this study, much emphasis was given 
to systematic classification of clinical presentation in combination with 
MRI characteristics. All patients were classified by the local investigators 
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as having mono- or polysymptomatic disease. In the study protocol, 
polysymptomatic onset was defined as ‘evidence of more than one 
clinical lesion’.  In the central reading centre at the VU Medical Centre all 
patients were subsequently classified as mono- or multifocal according 
to a standardized scheme, as previously described (Uitdehaag et al. 
227-31). Briefly, on basis of the neurological symptoms the location 
of the minimum number of lesions that could explain all symptoms is 
determined. Subsequently, from all information from the neurological 
examination it is decided whether these abnormalities could in any 
way be explained by the already identified clinical lesions. If not, this 
would indicate the presence of an additional clinical lesion. Patients 
thus classified as having evidence of one clinical lesion were called 
monofocal, patients thus classified as having evidence of more than 
one clinical lesion were called multifocal. This classification was done in 
consensus by two neurologists masked for the MRI results. 
At study entry all patients had a brain MRI done both pre and post 
gadolinium, according to protocol. All MRI studies were sent to the 
Image Analysis Centre in Amsterdam for centralised analysis of T2 
hyperintense, T1 gadolinium enhancing and T1 hypointense lesions, as 
well as for fulfilment of the criteria for dissemination in space according 
to the IP criteria. Since for the present study we were only interested in 
dissemination in space and not in dissemination in time, we only used 
cross sectional MRI data.
Statistical tests were performed using SPSS software (Version 11.0). 
For qualitative data chi-square tests were applied. For quantitative data 
t-tests were applied after checking if data were approximately normally 
distributed. If that was not the case either log transformation was 
performed or Mann-Whitney U test was applied. Reported p-values are 
based on two-tailed significance tests. The threshold for significance was 
set at 0.05.
Results: 
MRI T2 lesion counts as well as clinical data were available for all 487 
randomized patients. The number of T1 hypointense lesions was missing 
in three cases, the number of gadolinium enhancing lesions in four cases. 
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In four cases, the local investigator changed the classification between 
screening and baseline (as these patients developed new symptoms 
after the initial screening examination). Median age was 30 years (range 
18-45), 70% of the patients were female. Based on the centrally applied 
classification scheme, 254 patients were classified as monofocal and 
233 as multifocal. 
As can be seen in Table 1, age and gender distribution were similar 
for monofocal and multifocal patients. The median number of T2 lesions 
in the monofocal cases was 15.5 versus 21 in the multifocal cases 
(p=0.016). The median number of T1 hypointense lesions was 1 in the 
monofocal and 2 in the multifocal group (p=0.008). Patients presenting 
with multifocal symptoms and signs were more likely to fulfil more criteria 
for dissemination in space on brain MRI as incorporated in the IP criteria 
than monofocal patients (chi square test for trend p=0.005) (Figure 1). 
As overall differences between the classification by the local 
investigator and the centrally applied classification system were likely 
to be very small due to the large overlap between the groups, we 
separately analysed discrepant cases (Table 2). Of the 290 patients 
(60%) who were classified by the local neurologist as having evidence of 
one clinical lesion (‘monosymptomatic’), 61 were centrally reclassified as 
multifocal whereas the other 229 cases were judged to be monofocal. Of 
Table 1. Baseline characteristics
Randomized 
patients (n=487)
Monofocal 
(n=254)
Multifocal 
(n=233)
Age in yrs (range) 31 (18-45) 30 (18-45) 31 (18-45)
Gender, Female 343 (70%) 169 (67%) 174 (75%)
Median T2 lesions (IQR) 17 (7-38) 15.5 (6-36)** 21 (8-41)**
Median T1 hypo intense lesions (IQR) 2 (0-5) 1 (0-4)# 2 (0-6)#
Median T1 Gado lesions (IQR) 0 (0-1) 0 (0-1) 0 (0-1)
**p= 0.016 (t-test after log transformation)
#p= 0.008 (Mann Whitney test)
IQR= Interquartile range
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the 197 patients that were classified by the local investigator as having 
evidence of more than one clinical lesion (‘polysymptomatic’), 25 were 
centrally reclassified as monofocal, whereas the other 172 patients were 
classified as multifocal. Comparing these four subgroups, cases that were 
Table 2. Differences between mono-/multisymptomatic and mono-/multifocal classification 
Median no of T2 
lesions (IQR)
Median no of T1 hypo 
intense lesions (IQR)
Median no of T1 
Gd lesions (IQR)
Monosymptomatic1 
(n=290)
Monofocal2 
(n=229)
14 (6-35)* 1 (0-4) 0 (0-1)
Multifocal2 
(n=61)
22 (11-40)* 2 (1-5) 0 (0-1)
Polysymptomatic1  
(n=197)
Monofocal2 
(n=25)
24 (12-38) 2 (0-8) 1 (0-3)
Multifocal2 
(n=172)
19 (8-41) 2 (0-7) 0 (0-2)
1 classification by local investigator
2 central classification applying new system
*p= 0.01(t-test on log transformed values)
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Figure 1. Fulfillment of IP MRI criteria for dissemination in space in monofocal and 
multifocal patients
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centrally reclassified from ‘monosymptomatic’ to multifocal had more T2 
hyperintense lesions than those classified unanimously as monofocal 
(Table 2). Most of these patients were multifocal on signs (50/61); 38 of 
these presented with an optic neuritis of which 18 (47%) were multifocal 
on additional pyramidal and 9 (24%) on additional brainstem signs. In 
contrast, MRI characteristics of patients who were reclassified from 
‘polysymptomatic’ to monofocal did not differ from patients who were 
classified unanimously as multifocal. 
Discussion:
Although a diagnosis of MS according to the International Panel on the 
diagnosis of MS guidelines depends, to a great extent, on the interpretation 
of clinical findings, no clear guidance for their interpretation has been 
presented. In this study, we evaluated the relation between a recently 
published proposal for clinical classification (Uitdehaag et al. 227-31), 
which interprets clinical findings in terms of the presumed presence of 
one (monofocal) or at least two (multifocal) clinical anatomical lesions, 
and MS related abnormalities on MRI of the brain.  Our hypothesis 
was that patients who were classified as having multifocal disease on 
the basis of clinical findings had more MRI abnormalities than those 
classified as being monofocal.
Whereas all patients included in this study have limited clinical disease 
(first episode of neurological dysfunction, frequently monosymptomatic) 
they already have significant numbers of brain lesions on their brain MRI. 
This is a well-known phenomenon (Comi et al. 1576-82) related to the 
fact that MRI is more sensitive in picking up disease activity, including 
subclinical activity. In this specific study the number of MRI abnormalities 
was higher than in an unselected CIS population, since a minimum 
number of two asymptomatic brain lesions was required as inclusion 
criterion. Therefore, it remains to be evaluated whether the results of this 
study can be generalized to an unselected population of CIS patients 
which also includes patients with less than 2 asymptomatic lesions.
Compared to patients classified as monofocal, indeed, multifocal 
patients had significantly more T2 hyperintense, and T1 hypointense 
(‘black holes’) lesions, and fulfilled more MRI criteria for dissemination 
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in space as incorporated in the IP criteria. Apparently the clinical 
classification is reflected in MRI measures that represent the total burden 
of disease, the more destructive lesions, as well as the distribution 
of lesions in more or less MS specific regions of the brain, thereby 
suggesting that it does have clinical utility. Considering that MRI is a far 
more sensitive measure of disease activity than clinical episodes are 
(Isaac et al. 1511-15;Willoughby et al. 43-49), it is not surprising that the 
relation between the clinical classification and MRI is only weak and that 
there is a large overlap between the lesion numbers in the mono- versus 
multifocal cases. 
The systematic approach as introduced by the clinical classification 
scheme induces two types of classification changes. In the first place, some 
patients who were judged to have one clinical lesion were reclassified as 
multifocal on the basis of findings at neurological examination. The current 
study strongly suggests that these often subtle abnormalities do have an 
anatomical basis: ‘monosymptomatic’ patients who were clinically (re)
classified as multifocal had more MRI lesions than those classified as 
monofocal. In the second place, patients who were ‘polysymptomatic’ 
could be classified as monofocal if their symptoms were judged to be 
possibly explained by only one strategically located anatomical lesion. 
The correlation with MRI does not provide a justification for this, since, 
among polysymptomatic patients, lesion numbers were not significantly 
different when comparing mono- versus multifocal.
In conclusion, the current study does provide justification for a 
recently proposed clinical classification system to be used in patients who 
present with a first episode suggestive of MS in that ‘clinically multifocal’ 
is associated with more lesions on MRI. This is especially true for those 
patients who present with monosymptomatic disease (i.e. isolated optic 
neuritis or spinal cord syndrome). Further studies should address the 
question whether the proposed clinical classification also has an impact 
on future disease course or treatment response.
CHAPTER 3
78
Reference List
Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study 
of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 
346(3):158-164.
Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al. Effect of early interferon 
treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 
2001; 357(9268):1576-1582.
Isaac C, Li DK, Genton M, Jardine C, Grochowski E, Palmer M et al. Multiple sclerosis: a 
serial study using MRI in relapsing patients. Neurology 1988; 38(10):1511-1515.
Kappos L., Polman CH, Freedman MS, Edan G, Hartung H, Miller D et al. Betaferon in 
Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): clinical results. 
Mult Scler 2005; Suppl 1(11):S10.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended 
diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the 
diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1):121-127.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic 
criteria for multiple sclerosis: 2005 revisions to the «McDonald Criteria». Ann Neurol 
2005; 58(6):840-846.
Schumacher GA, Beebe GW, Kibler RF, et al. Problems of experimental trials of therapy in 
multiple sclerosis. Annals of the New York Academy of Science 1965;(122):552-568.
Uitdehaag BM, Kappos L, Bauer L, Freedman MS, Miller D, Sandbrink R et al. Discrepancies 
in the interpretation of clinical symptoms and signs in the diagnosis of multiple 
sclerosis. A proposal for standardization. Mult Scler 2005; 11(2):227-231.
Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic 
resonance scanning in multiple sclerosis: a second prospective study in relapsing 
patients. Ann Neurol 1989; 25(1):43-49.
EARLY PROGNOSIS
79
CHAPTER 3.2
mri characteristics are preDictive 
for cDms in monofocal, but not in 
multifocal patients with a clinically 
isolateD synDrome
J.M. Nielsen, 
C. Pohl, 
C. H. Polman, 
F. Barkhof, 
M. S. Freedman, 
G. Edan, 
D. H. Miller, 
L. Bauer, 
R. Sandbrink, 
L. Kappos, 
B.M.J. Uitdehaag
BMC Neurol. 2009 May 20;9:19.
CHAPTER 3
80
Abstract
Background:  To diagnose multiple sclerosis (MS), evidence for dissemi-
nation in space and time is required. There is no clear definition on how 
symptoms and signs of a patient indicate clinical dissemination in space. 
To provide a uniform approach on this subject, a clinical classification 
system was described recently differentiating patients with mono- and 
multifocal clinical presentation. Here we assess the predictive value of 
clinically defined dissemination in space at first presentation for time to 
clinically definite MS (CDMS).   
Methods: Four hundred and sixty-eight patients with a first episode 
suggestive of MS were classified as clinically mono- or multifocal by 
two neurologists blinded to magnetic resonance imaging (MRI) results. 
These patients were part of the BENEFIT study in which 292 patients 
were randomized to interferon beta-1b (IFNB-1b) and 176 to placebo. 
By using Kaplan-Meier statistics the risk for CDMS was studied in mono- 
and multifocal patients of the placebo group, both with and without taking 
into account MRI measures of potential prognostic relevance.
Results: Time to CDMS was similar in monofocal and multifocal patients. 
In monofocal patients, the risk for CDMS over 2 years was significantly 
higher when ≥ 9 T2 lesions or at least one Gd-enhancing lesion were 
present at the first event or 3 or 6 months after the first event. In patients 
with multifocal presentation, these MRI measures had no significant 
added value in predicting time to CDMS. 
Conclusions: These data indicate that a carefully performed neurological 
assessment of symptoms and signs, combined with lesions on MRI, is 
important for defining the risk of conversion to CDMS. The Benefit trial 
has been registered under NCT00185211 www.clinicaltrials.gov 
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Background
Multiple sclerosis (MS) has a highly variable disease course (Confavreux, 
Vukusic, and Adeleine 770-82) and knowledge of factors that predict 
subsequent disease course in individual patients with a first event 
suggestive of MS (also called patients with a clinically isolated syndrome: 
CIS) is limited.  
In CIS patients, magnetic resonance imaging (MRI) characteristics 
have been described as a predictor of conversion to clinically definite 
MS (CDMS) and of the subsequent disease course. CIS patients with an 
abnormal cerebral MRI scan at presentation have a substantially higher 
long-term risk of conversion to CDMS than those with a normal cerebral 
MRI (Brex et al. 158-64). Diagnostic guidelines for MS include detailed 
MRI rules for the definition of dissemination in space of MS-specific 
pathology (McDonald et al. 121-27;Polman et al. 840-46). In untreated 
(Korteweg et al. 221-27) and treated (Barkhof et al. 718-24) CIS patients 
fulfillment of these criteria is associated with a high risk of CDMS.
According to the recommendations of the International Panel (IP) 
on the Diagnosis of Multiple Sclerosis, disease dissemination in CIS 
patients can also be identified by clinical examination of symptoms and 
signs at the first clinical event (McDonald et al. 121-27). In contrast to a 
detailed algorithm on the use of MRI criteria, however, it was left unclear 
how clinical disease dissemination should be evaluated. Recently it was 
shown that the clinical assessment of disease dissemination can vary 
widely between physicians (Uitdehaag et al. 227-31). To standardize 
these assessments, a clinical classification system was proposed 
(Uitdehaag et al. 227-31). This system was centrally applied to patients 
of the BEtaferon®/BEtaseron® in Newly Emerging multiple sclerosis 
For Initial Treatment (BENEFIT) study, a study evaluating the impact 
of interferon beta-1b (IFNB-1b) in CIS patients. By analyzing baseline 
data from this study we have recently shown that patients with clinical 
dissemination in space (multifocal, indicating more than one clinical 
lesion) had more lesions on their MRI than monofocal patients (those 
exhibiting symptoms and signs from only one clinical lesion) (Nielsen et 
al. 717-21). 
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In the present study we assessed the prognostic value of this clinical 
classification system (Uitdehaag et al. 227-31) for conversion to CDMS 
and the added value of potentially prognostic MRI parameters, by 
analyzing data obtained during the placebo-controlled treatment period 
of the BENEFIT study.
Methods
Study design, patients, and procedures
BENEFIT is a multicenter study comparing IFNB-1b to placebo in CIS 
patients for up to 2 years, followed by a follow-up period with IFNB-1b for 
up to 5 years after the CIS. For the present analyses we used data from 
the placebo-controlled first 2 years of the study. The design and main 
outcomes of the placebo-controlled phase of the BENEFIT trial have 
been reported elsewhere (Kappos et al. 1242-49). Patients completed 
the placebo-controlled phase of BENEFIT if they either reached 24 
months of follow-up or were diagnosed with CDMS. Briefly, inclusion 
criteria encompass: age between 18 and 45 years, presentation with a 
first neurological event suggestive of MS, and the presence of at least 
two clinically silent lesions on a T2-weighted brain MRI scan with a 
minimum size of 3 mm, at least one of which was ovoid, periventricular, 
or infratentorial. 
Patients were randomly assigned in a 5:3 ratio to IFNB-1b 250 µg or 
placebo, by subcutaneous injection every other day. Study treatment was 
initiated within 60 days of confirmation of the first clinical event. Regular 
visits were scheduled for collection of clinical, MRI findings, and other data 
on disability progression as measured by the expanded disability status 
scale (EDSS) (Kurtzke 1444-52), All MRI scans were performed with 0.1 
mmol/kg gadolinium. MRI findings and other parameters at months 3, 6, 
9, 12, 18, and 24. Several MRI parameters were analyzed; in particular, 
number of: gadolinium (Gd)-enhancing lesions, hyperintense T2 lesions, 
hypointense T1 lesions, and newly active lesions (NALs). A NAL was 
defined as a new T2 hyperintense or Gd-enhancing lesion, or a newly 
enlarging T2 lesion. The numbers and volumes of hyperintense lesions on 
T2-weighted images and Gd-enhancing lesions on T1- weighted images 
were centrally evaluated at the Image Analysis Center in Amsterdam, 
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The Netherlands. MRI analyses were performed by expert readers who 
were blinded to the patients’ clinical classification. 
As MS according to the criteria proposed by the IP on the Diagnosis 
of Multiple Sclerosis (McDonald et al. 121-27) was one of the primary 
outcome measures, much emphasis was placed on the clinical 
classification of patients. On the basis of all available information of 
clinical signs and symptoms, as documented by the local investigator, 
patients were classified centrally by the consensus of two neurologists 
(CHP and BMJU) as having an either monofocal or multifocal disease 
presentation according to the previously described standardized scheme 
(Uitdehaag et al. 227-31). Briefly, on the basis of the neurological 
symptoms the minimum number of central nervous system (CNS) 
areas that could explain all symptoms was determined (=monofocal 
or multifocal presentation as defined by symptoms). Subsequently, 
it was decided whether abnormalities as revealed by the neurological 
examination (=signs) indicated the presence of additional lesions in the 
CNS (=monofocal or multifocal presentation as defined by signs). 
In the case of a multifocal presentation it was then decided whether 
the patient’s multifocal classification was purely based on multiple 
presenting symptoms (these patients are denoted as multifocal patients 
by symptoms) or whether clinical signs indicated additional CNS lesions 
that did not correspond to any of the presenting symptoms (these patients 
are denoted as multifocal patients by signs). This sub classification 
of multifocal patients was carried out under the hypothesis that such 
additional clinical signs (in the absence of concomitant symptoms) might 
point to subclinical disease activity preceding the reported onset.    
Statistical analysis
The following analyses were performed to evaluate different disease 
characteristics of 1) monofocal versus multifocal CIS patients; and 2) 
multifocal CIS patients by signs only versus by symptoms only. In order 
to avoid any influence of IFNB-1b treatment on the results, analyses on 
time to CDMS were only performed in placebo patients whilst analyses 
on baseline parameters were performed in the total patient cohort. 
Analyses were performed using SAS.
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Comparison of key baseline characteristics between mono- and multifocal 
patients at the first event and between the multifocal subgroups by signs 
and by symptoms (all patients)
The following parameters were analyzed: Age, sex, steroid use at 
first event, EDSS at screening, positive CSF findings, number of T2-
hyperintense lesions, number of / proportion of subjects with at least 
one Gd-enhancing lesion(s), proportion of subjects with at least one T1 
hypointense lesion. 
Comparison of time to CDMS and MRI disease activity between the 
monofocal and multifocal patients and between the multifocal subgroups 
by signs and by symptoms (placebo patients)
Time to CDMS was analyzed as a measure for clinical activity and the 
annualized cumulative number of NALs over the study  was analyzed as 
a measure of subclinical activity. 
Comparison of the impact of MRI findings at screening, month 3, and 
month 6 on time to CDMS within the monofocal and multifocal group 
separately (placebo patients) 
These analyses were only performed on data from the mono- and 
multifocal subgroups, as patient numbers were too small to further stratify 
the multifocal subgroups by symptoms and by signs. The following 
MRI parameters were evaluated: presence of Gd-enhancement, or 
pronounced disease dissemination (≥ 9 T2 lesions) on the screening 
MRI; new Gd-enhancement at months 3 or 6.  
Dichotomous variables were compared using Fisher’s exact test. 
Continuous variables were compared using the Mann-Whitney U-test 
(comparison of the cumulative number of NALs was done by a Wilcoxon 
test). Kaplan-Meier survival analysis was used to analyze time to CDMS. 
Group comparisons for this outcome measure were performed using 
the log-rank test. Interaction of clinical mono-/multifocality and MRI 
parameters was analyzed by Cox proportional hazards regression. 
Reported p-values are based on two-tailed significance tests, with the 
threshold for significance set at 0.05. Analyses were performed post hoc 
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on data from the placebo-controlled period of the BENEFIT study for all 
patients who were randomized and received study medication at least 
once. 
Results
Four hundred and eighty-seven patients were randomized and 468 
started treatment in the BENEFIT study. Four hundred and thirty-seven 
of these (93.6%) completed the placebo-controlled study. Two hundred 
and ninety-two patients received IFNB-1b and 176 received placebo. 
The main outcome data have previously been published (Kappos et al. 
1242-49). 
Table 1.  Disease characteristics of monofocal vs. multifocal CIS patients 
All Monofocal Multifocal p-value*
N 468 (100%) 246 (53%) 222 (47%)
Sex – % of females 71% 66% 76% 0.0325†
Age, median  
(quartiles)
30 
(24–37)
29 
(24–37)
31 
(25–37)
0.0820‡
Steroid treatment – % 71% 72% 70% 0.6835†
EDSS (screening), median (quartiles) 2 
(1–2.5)
1.5 
(1–2)
2 
(1.5–2.5)
<0.0001‡
CSF positive of samples taken – % 267/314 
85% (57%)
149/176 
85% (61%)
118/138 
86% (53%)
0.8745†
Number of T2 lesions, median 
(quartiles)
17 
(7–38)
16 
(6–36)
21 
(8–41)
0.0182‡
At least one Gd-enhancing lesion – % 42% 42% 43% 0.9254†
At least one T1 hypointense lesion – % 68% 63% 73% 0.0300†
*Compares monofocal vs. multifocal patients. P-value in bold when p < 0.05
†Fisher’s exact test, ‡Mann-Whitney U-test
EDSS: expanded disability status scale, CSF: cerebrospinal fluid, Gd: gadolinium
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Comparison of key baseline characteristics of mono- and multifocal CIS 
patients (all patients)
Two hundred and forty-six (53%) patients were classified as monofocal 
and 222 (47%) as multifocal. Baseline characteristics of mono- and 
multifocal patients are outlined in Table 1 and have been reported 
previously (Nielsen et al. 717-21). In summary: Multifocal patients had a 
higher number of T2-hyperintense lesions (p = 0.018) and more frequent 
T1-hypointense lesions (p = 0.030). 
Comparison of time to CDMS and MRI disease activity between the 
monofocal and multifocal patients (placebo patients)
Neither time to CDMS (Hazard ratio / ± 95% CI: 1.09 / 0.70-1.71; p = 0.71) 
nor the annualized cumulative number of NALs (p=0.47 by Wilcoxon test 
and p = 0.51 by baseline adjusted non-parametric ANCOVA, see Table 
2) differed significantly between mono- and multifocal placebo patients. 
Comparison of the impact of MRI findings at screening, month 3, and 
month 6 on time to CDMS within the monofocal and multifocal group 
separately (placebo patients)
The risk of CDMS was significantly higher in monofocal placebo patients 
with ≥ 9 T2-hyperintense lesions at screening (Hazard ratio / ± 95% CI: 
2.13 / 1.05-4.34; p = 0.032), with at least one Gd-enhancing lesion at 
screening (Hazard ratio / ± 95% CI: 2.28 / 1.24-4.18; p = 0.006), with 
at least one Gd-enhancing lesion at month 3 (Hazard ratio / ± 95% CI: 
3.03 / 1.51-6.07; p < 0.002), and with at least one Gd- enhancing lesion 
at month 6 (Hazard ratio / ± 95% CI: 3.98 / 1.84-8.65; p < 0.001) than in 
monofocal placebo patients without these criteria (Figure 1, 2). 
The risk of CDMS was not significantly higher in multifocal placebo 
patients with ≥ 9 T2-hyperintense lesions at screening (Hazard ratio / 
± 95% CI: 0.74 / 0.36-1.54;  p = 0.42), with at least one Gd-enhancing 
lesion at screening (Hazard ratio / ± 95% CI: 0.96 / 0.48-1.93; p = 0.92), 
with at least one Gd-enhancing lesion at month 3 (Hazard ratio / ± 95% 
CI:1.03 /0.48-2.23; p = 0.94), and with at least one Gd-enhancing lesion 
at month 6 (Hazard ratio / ± 95% CI: 2.04 / 0.86-4.86; p = 0.11), than in 
multifocal placebo patients without these criteria (Figure 1, 2). 
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Table 2.  Disease course of monofocal vs. multifocal placebo patients after the CIS
All Monofocal Multifocal p-value*
N 176 93 83
CDMS  %* over  2 years 45% 47% 44% 0.7052†
Median annualized cumulative number  
of NALs over the study (quartiles)
3.2
(0.96–10.4)
3.0 
(0.5–9.4)
3.6 
(1.0–12.5)
0.4698‡
*Compares monofocal vs. multifocal patients 
NAL: newly active lesion
CDMS: clinically definite MS
†Kaplan-Meier estimate at day 720, Log rank test 
‡Wilcoxon test  
Table 3.  Disease characteristics of multifocal patients by symptoms and by signs at the 
CIS 
Multifocal Multifocal by 
symptoms
Multifocal  
by signs  
p-value
N 222 122 100
Sex – % of females 76% 77% 74% 0.6389†
Age, median  
(quartiles)
31 
(25-37)
30.5 
(25-36)
31 
(25-38)
0.7919‡
Steroid treatment – % 70% 72% 67% 0.4632†
EDSS (screening), median 
(quartiles)
2 
1.5-2.5
2 
1.5-2.5
2 
1.5-2.5
0.9598‡
CSF positive of samples 
taken – %
118/138 
86% (53%)
62/70 
89% (51%)
56/68 
82% (56%)
0.3405†
Number of T2 lesions, median 
(quartiles)
21 
(8-41)
19.5 
(8-47)
22.5 
(9-40)
0.9130‡
At least one Gd-enhancing 
lesion – % 
42% 45% 39% 0.3376†
At least one T1 hypo intense 
lesion – %
73% 71% 74% 0.7627†
†Fisher’s exact test, ‡Mann-Whitney U-test , EDSS: expanded disability status scale, CSF: 
cerebrospinal fluid, Gd: gadolinium
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This differential effect of MRI parameters on the risk of conversion 
to CDMS in these two patient groups (monofocal and multifocal) was 
confirmed by Cox proportional hazards regression. This analysis 
revealed a significant interaction between mono-/multifocality and either 
≥ 9 T2-hyperintense lesions at screening (Hazard ratio / ± 95% CI: 0.35 
/ 0.13-0.96; p = 0.042) or at least one Gd-enhancing lesion at month 3 
(Hazard ratio / ± 95% CI: 0.34 / 0.12-0.96; p = 0.042), but not between 
mono/multifocality and at least one Gd-enhancing lesion at screening 
(Hazard ratio / ± 95% CI: 0.42 / 0.17-1.05; p=0.064) or at least one Gd-
enhancing lesion at month 6 (Hazard ratio / ± 95% CI: 0.50 / 0.16-1.6; p 
= 0.246).
Comparison of key baseline characteristics of multifocal patients by 
symptoms and multifocal patients by signs at the first event (all patients)
One hundred and twenty-two (55%) of the 222 multifocal patients 
presented by symptoms, while 100 (45%) presented by signs (the 
classification of these latter patients was based on the presence of 
signs indicating an additional clinical lesion, according to the central 
classification). Baseline characteristics did not differ significantly between 
multifocal patients by symptoms and by signs (Table 3). 
Table 4.  Disease course of multifocal placebo patients by symptoms and by signs after 
the CIS 
All 
multifocal 
Multifocal by 
symptoms 
Multifocal 
by signs
p-value*
N 83 50 (60%) 33 (40%)
CDMS  %* over  2 years 44% 49% 37% 0.3554†
Median annualized cumulative number 
of NALs over the study (quartiles)
3.6
(1.0–12.5)
5.3
(1.6–13.4)
2.6
(0–7.0)
0.0424‡
*Compares multifocal patients by symptoms vs. multifocal patients by signs
 †Kaplan-Meier estimate at day 720, Log rank test 
‡Wilcoxon test
CDMS: clinically definite MS, NAL: newly active lesion, Gd: gadolinium
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Comparison of time to CDMS and MRI disease activity between multifocal 
patients by symptoms and by signs (placebo patients)
There was no statistically significant difference between the survival 
curves of “Time to CDMS” comparing multifocal placebo patients by 
symptoms and by signs (Hazard ratio / ± 95% CI: 0.72 / 0.36-1.45; p 
= 0.36). Multifocal placebo patients by symptoms developed a higher 
annualized number of NALs over the study period (p = 0.042 by Wilcoxon 
test; Table 4, supplemental data file).
Discussion
In a cross-sectional analysis of baseline data from CIS patients in the 
BENEFIT study we have recently demonstrated that clinical dissemination 
of the disease corresponds to more widespread subclinical CNS pathology 
as detected by cerebral MRI (Nielsen et al. 717-21). In the present study 
we addressed whether clinical disease dissemination in these patients 
also indicates an increased risk for subsequent disease activity, and 
whether the presence versus absence of clinical dissemination has an 
impact on the prognostic value of MRI parameters. 
Patients with monofocal versus multifocal clinical presentation did 
not differ in terms of their risk for CDMS or with respect to the annualized 
number of NALs over the 2-year placebo-controlled period, as has been 
reported previously (Polman et al. 480- 87). However, we did find that MRI 
findings of subclinical disease dissemination or activity have a different 
prognostic value for development of CDMS in mono- versus multifocal 
CIS patients. The presence of at least nine T2 lesions or at least one Gd-
enhancing lesion during screening was predictive for time to CDMS in 
monofocal patients though not in multifocal patients. Similar observations 
were made for the prognostic value of a new Gd-enhancing lesion on an 
MRI scan performed at month 3 or month 6. Thus, in monofocal, but not 
in multifocal patients the risk for CDMS depends on MRI findings. This 
differential impact of MRI findings in CIS patients with clinical monofocal 
versus clinical multifocal presentation was supported by a significant 
interaction between the impact of clinical mono-/multifocality and ≥ 9 T2 
lesions at baseline and at least one Gd-enhancing lesion at month 3 on 
time to CDMS.
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These findings strongly suggest that only in CIS patients with monofocal 
clinical presentation do MRI findings have prognostic value. We 
hypothesize that, whilst in monofocal CIS patients more pronounced 
subclinical disease dissemination might primarily reflect more active 
disease, similar findings in multifocal patients may be more indicative 
of prolonged subclinical disease evolution, and as such MRI adds less 
information in these patients. 
Figure 1  Time to CDMS in mono- vs. multifocal placebo patients stratified by MRI findings 
at screening.
Note the predictive value of baseline MRI findings in monofocal patients (left panels) and 
the absence of predictive value of MRI in multifocal patients (right panels). There was a 
significant interaction between mono-/multifocality and the presence of either ≥ 9 T2 hyper 
intense lesions (p = 0.042). CDMS: clinically definite MS.
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To further elaborate on this hypothesis we expanded these 
comparisons to subgroups of multifocal patients: those by symptoms 
and those by signs, under the assumption that especially those patients 
multifocal by signs may have had an earlier event that was asymptomatic 
or forgotten, and therefore may have a longer and more benign form 
of the disease. We found similar baseline characteristics and only 
a nonsignificant difference in time to CDMS in these subgroups. The 
Figure 2   Time to CDMS in mono- vs. multifocal placebo patients stratified by MRI findings 
at month 3 and month 6.
 
Note the significant predictive value of months 3 and 6 MRI findings in monofocal patients 
(left panels) and the absence of predictive value in multifocal patients (right panels). There 
was a significant interaction between mono-/multifocality and the presence of at least one 
Gd-enhancing lesion at month 3 (both p = 0.042). CDMS: clinically definite MS.
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observation that multifocal placebo patients by symptoms tended to 
have more active MRI lesions during the study than multifocal placebo 
patients by signs further supports our hypothesis that the former may be 
considered more acute and at higher risk for future disease activity than 
a multifocal patient by signs in whom a longer subclinical disease history 
might be assumed. Differences with respect to patients showing at least 
one Gd-enhancing lesion (more in patients multifocal by symptoms) and 
patients showing at least one T1-hypointense lesion (more in patients 
multifocal by signs) as shown in Table 3, although not significant, are 
also supportive of our hypothesis.
We compared our results to those obtained in the Early Treatment of 
MS (ETOMS) (Comi et al. 1576-82) and Controlled High-Risk Avonex® 
Multiple Sclerosis Prevention Study (CHAMPS) (Jacobs et al. 898-904) 
studies, other interventional trials in CIS patients where comparable 
analyses were performed. In the ETOMS study, the presence of three 
or more MRI criteria as incorporated in the International Panel on the 
Diagnosis of Multiple Sclerosis guidelines (McDonald et al. 121-27) was 
also predictive for CDMS only in patients who were classified as clinically 
unifocal (Barkhof et al. 718-24). Unlike our observation, multifocal 
patients in ETOMS had a higher risk for CDMS. This difference in the 
predictive value of “multifocality” in the BENEFIT and the ETOMS cohort 
may result from the different methods used to classify patients in the 
two studies. Evaluation of clinical dissemination in ETOMS was based 
on the local investigator’s assessment, whilst multifocality in BENEFIT 
was based on a central assessment procedure according to a proposed 
classification system of all presenting clinical symptoms and signs. Thus, 
multifocality in BENEFIT was also assumed in patients who, in addition 
to a monosymptomatic presentation (e.g. optic neuritis), presented with 
additional clinical signs (e.g. pyramidal dysfunction as indicated by 
extensor plantar response) indicating an additional clinical lesion. Also, 
in a post hoc analysis of the CHAMPS study (Kinkel RP, O’Connor, and 
Kremenchutzky M Abstract P04.070.) all patients were reclassified, 
taking into account the results of neurological examinations at baseline. 
In a multivariate analysis, classification by focality was not predictive of 
conversion to CDMS, which is in line with our results.
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All patients in BENEFIT, ETOMS, and CHAMPS had a minimum number 
of asymptomatic T2 lesions; therefore it is unclear whether these results 
also can be applied to CIS patients with fewer or no lesions. Further 
limitations of our analyses should be considered. All subgroup analyses 
were performed post hoc and our results need confirmation, particularly 
the novel findings in the subgroups of multifocal CIS patients. However, 
we would like to emphasize the similarities between our findings and the 
ETOMS study (Barkhof et al. 718-24) in terms of the lack of impact of 
MRI findings in multifocal patients on the risk of CDMS. 
Conclusion: 
To summarize, MRI lesions may generally be interpreted as indicators of 
past and future disease activity in patients with monofocal presentation, 
though not in multifocal patients, in whom their presence does not add to 
the risk as defined by the clinical evaluation only. Our findings show that 
a carefully performed neurological assessment of symptoms and signs 
in CIS patients is important to define the risk of conversion to CDMS and 
the potential added value of MRI investigations.  
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CHAPTER 4:
general Discussion  
anD future perspectives
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In this thesis we evaluated different properties of diagnostic guidelines 
for MS. Our results first suggest that the 2005 McDonald criteria, along 
with the proposed criteria by Swanton et al. for MS, are indeed specific 
in discriminating MS from other diagnostically difficult cases, in contrast 
to criteria as proposed by the American Academy of Neurology (AAN). 
Secondly, our results suggest that when using the present MS guidelines 
in the clinical practice of a specialized MS center, only few patients 
initially not diagnosed with MS, after long term follow up, will turn out to 
have MS or develop another neurological disease. Thirdly, our results 
suggest that in multifocal patients, who fulfill criteria for dissemination in 
space (DIS) on clinical grounds, more MRI parameters are present which 
are known to represent the pathophysiological burden of the disease, 
than in monofocal patients. Finally, we demonstrated that in monofocal 
patients, the presence of >/= 9 T2 lesions or enhancement of lesions on 
MRI, is predictive for the development of CDMS, whereas this is not the 
case for multifocal patients. In this section the main outcomes will be 
discussed as well as future perspectives. 
Differentiating MS from other neurological diseases
We confirmed the specificity of the MRI criteria for DIS (McDonald et 
al. 121-27;Polman et al. 840-46;Swanton et al.) as incorporated in the 
diagnostic criteria for MS. As differentiating  MS from other diseases is 
a key issue in clinical practice, it is of great importance to study  the 
performance of the MRI criteria and MS guidelines in patients suspected 
of MS,  yet who are ultimately not diagnosed with MS. Clearly the criteria 
should not be met  in these patients. We investigated (2.1) the ability 
of the DIS MRI criteria to differentiate MS from other diagnoses in 
this population and found high specificity for the 2001 McDonald and 
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2005 Revised McDonald criteria, as well as for criteria as proposed by 
Swanton et al. Several other papers have reported on specificity of the 
different diagnostic MRI criteria and found high specificity (Dalton et al. 
47-53;Korteweg et al. 221-27;Swanton et al.;Swanton et al. 677-86). 
Even though, in these papers specificity was calculated in patient groups 
in whom other diagnoses had been excluded before. Reported specificity 
in these papers can therefore  be perceived as a parameter for disease 
progression, rather than as an instrument to differentiate between MS 
and other neurological diseases. Whereas  an MS diagnosis requires 
DIS as well as DIT, we only studied dissemination in space (DIS) criteria. 
Both have been proven specific for a definite MS diagnosis, but especially 
the latter component (Swanton et al.) (Dalton et al. 673-76;Swanton et al. 
677-86).  Therefore, the specificity in our study of the different criteria is 
likely to be systematically underrated, although is unclear to what extent 
as there are no other studies investigating DIS and/or DIT in patients 
suspected of MS, but ultimately diagnosed with another disease. 
However, it is unlikely that this underestimation would be much larger 
for the AAN than for the McDonald or Swanton criteria, therefore  the 
difference in specificity will most likely remain (in some measure). 
Striving for utmost  specificity of (MRI) criteria is one way of avoiding 
an incorrect MS diagnosis. Consecutive versions of published diagnostic 
guidelines for MS (McDonald et al. 121-27;Polman et al. 840-46;Polman 
et al. 292-302;Poser et al. 227-31;Schumacher GA et al. 552-68) demand 
that: ‘there must be no better explanation for the clinical presentation’. 
Another similar way to avoid an incorrect MS diagnosis, is  to find ‘a better 
explanation for the clinical picture’ by defining alternative diagnoses of 
MS, and specific features that positively indicate another diagnosis. 
We’ve described the alternative diagnoses we found in the retrospective 
consecutive patient group (chapter 2.1 and 2.4) and in the case report 
(chapter 2.3). We found that the major differentially diagnostic group 
comprises of cerebrovascular disease and we found several  rarer 
diagnoses. In the past years two papers (Charil et al. 841-52;Miller et 
al. 1157-74) have reported on features (‘red flags’) positively indicating 
other diagnoses.  These papers report a consensus view of MS (MRI) 
specialists, as a first step, on differential diagnoses and an extensive list 
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of  MRI and clinical characteristics that are atypical for MS (‘red flags’) 
and characteristic of other diagnoses.  A more recent paper by Albertyn 
et al. (Albertyn et al. 678-84) found that in a general neurology practice 
those patients who did not meet  the diagnostic MS criteria after more 
than a median of 4 years of follow up, clearly had such red flags,  but  the 
presence of these red flags did not lead to other diagnoses. Therefore 
further defining differentiating characteristics of these alternative 
diagnoses should be a future goal. Diagnostic practical algorithms 
further focusing on and prioritizing these most prevalent and important 
differentially diagnostic diseases, such as cerebrovascular disease, and 
highlighting the differences of clinical and paraclinical investigations 
between such other diagnoses and MS, may  be helpful. Such an 
algorithm should be prospectively tested in the appropriate populations. 
Even though  it is unlikely that this process - which is different for each 
patient - will ever be fully covered by such an algorithm and replace 
clinical experience. 
Although with different versions of the McDonald criteria (McDonald 
et al. 121-27) (Polman et al. 840-46) accuracy has improved and an MS 
diagnosis can be made earlier, the criteria have been shown complex 
in clinical use (Hawkes and Giovannoni;Korteweg et al. 67-71;McHugh, 
Galvin, and Murphy 81-85). This is probably due  to the complexity of 
the MRI guidelines (Korteweg et al. 67-71), the  complexity of the clinical 
scheme to be followed, and ambiguous clinical definitions (Hawkes and 
Giovannoni). In patients suspected of MS in a general neurology practice, 
Table 1 criteria for DIS as incorporated in the McDonald criteria 2010 based on Swanton 
et al. 677-86
DIS Can Be Demonstrated by ≥1 T2 Lesiona in at Least 2 of 4 Areas of the CNS: 
Periventricular 
Juxtacortical 
Infratentorial 
Spinal cordb 
a Gadolinium enhancement of lesions is not required for DIS 
b If a subject has a brainstem or spinal cord syndrome these lesions are  excluded from the 
Criteria and do not contribute to the lesion count    
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Table 2. The 2010 McDonald criteria for diagnosis of MS (Polman et al. 292-302)
Clinical Presentation Additional Data Needed for MS Diagnosis
≥ 2 attacksa; objective clinical
evidence of ≥ 2 lesions or objective
clinical evidence of 1 lesion with
reasonable historical
evidence of a prior attackb
Nonec
≥ 2 attacksa; objective clinical
evidence of 1 lesion
Dissemination in space, demonstrated by:
≥ 1 T2 lesion in at least 2 of 4 MS-typical regions of 
the CNS (periventricular, juxtacortical, infratentorial, 
or spinal cord)d; or Await a further clinical attacka 
implicating a different CNS site
1 attacka; objective clinical
evidence of ≥ 2 lesions
Dissemination in time, demonstrated by:
Simultaneous presence of asymptomatic 
gadolinium-enhancing and nonenhancing lesions at 
any time; or A new T2 and/or gadolinium-enhancing 
lesion(s) on follow-up MRI, irrespective of its timing 
with reference to a baseline scan; or Await a second 
clinical attacka
1 attacka; objective clinical 
evidence of 1 lesion
(clinically isolated syndrome)
Dissemination in space and time, demonstrated by:
For DIS:
≥ 1 T2 lesion in at least 2 of 4 MS-typical regions of 
the CNS (periventricular, juxtacortical, infratentorial, 
or spinal cord)d; or
Await a second clinical attacka implicating a different 
CNS site; and
For DIT:
Simultaneous presence of asymptomatic 
gadolinium-enhancing and nonenhancing lesions at 
any time; or
A new T2 and/or gadolinium-enhancing lesion(s) 
on follow-up MRI, irrespective of its timing with 
reference to a baseline scan; or
Await a second clinical attacka
Insidious neurological progression
suggestive of MS (PPMS)
1 year of disease progression (retrospectively or 
prospectively determined) plus 2 of 3 of the following 
criteriad:
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1. Evidence for DIS in the brain based on ≥ 1 T2 
lesions in the MS-characteristic (periventricular, 
juxtacortical, or infratentorial) regions
2. Evidence for DIS in the spinal cord based on ≥ 2 
T2 lesions in the cord
3. Positive CSF (isoelectric focusing evidence of 
oligoclonal bands
and/or elevated IgG index)
If the Criteria are fulfilled and there is no better explanation for the clinical presentation, the diagnosis is 
‘‘MS’’; if suspicious, but the Criteria are not completely met, the diagnosis is ‘‘possible MS’’; if another 
diagnosis arises during the evaluation that better explains the clinical presentation, then the diagnosis 
is ‘‘not MS.’’
a An attack (relapse; exacerbation) is defined as patient-reported or objectively observed events typical 
of an acute inflammatory demyelinating event in the CNS, current or historical, with duration of at 
least 24 hours, in the absence of fever or infection. It should be documented by contemporaneous 
neurological examination, but some historical events with symptoms and evolution characteristic for 
MS, but for which no objective neurological findings are documented, can provide reasonable evidence 
of a prior demyelinating event. Reports of paroxysmal symptoms (historical or current) should, however, 
consist of multiple episodes occurring over not less than 24 hours. Before a definite diagnosis of MS can 
be made, at least 1 attack must be corroborated by findings on neurological examination, visual evoked 
potential response in patients reporting prior visual disturbance, or MRI consistent with demyelination in 
the area of the CNS implicated in the historical report of neurological symptoms.
b Clinical diagnosis based on objective clinical findings for 2 attacks is most secure. Reasonable historical 
evidence for 1 past attack, in the absence of documented objective neurological findings, can include 
historical events with symptoms and evolution characteristics for a prior inflammatory demyelinating 
event; at least 1 attack, however, must be supported by objective findings.
c No additional tests are required. However, it is desirable that any diagnosis of MS be made with 
access to imaging based on these Criteria. If imaging or other tests (for instance, CSF) are undertaken 
and are negative, extreme caution needs to be taken before making a diagnosis of MS, and alternative 
diagnoses must be considered. There must be no better explanation for the clinical presentation, and 
objective evidence must be present to support a diagnosis of MS.
d Gadolinium-enhancing lesions are not required; symptomatic lesions are excluded from consideration 
in subjects with brainstem or spinal cord syndromes.
MS = multiple sclerosis; CNS = central nervous system; MRI = magnetic resonance imaging; DIS = 
dissemination in space; DIT = dissemination in time; PPMS = primary progressive multiple sclerosis; 
CSF = cerebrospinal fluid; IgG = immunoglobulin G.
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an MS diagnosis was frequently made even though DIT was not present 
and an MRI was frequently not repeated (McHugh, Galvin, and Murphy 
81-85). To  improve accuracy and to simplify the diagnostic process, 
diagnostic criteria were proposed by Swanton et al. It was proposed to 
diminish the number of lesions, while retaining their specific locations 
as evidence for DIS (table 1). In these criteria at least 1 T2 lesion is 
required in at least 2 out of 4 for MS typical locations (periventricular, 
juxtacortical, infratentorial and spinal cord). In chapter 2.3 we compared 
the specificity of the (revised) McDonald MRI criteria to these Swanton 
criteria (Swanton et al.) and found comparable specificity. In a large 
multicenter study of CIS patients (Swanton et al. 677-86)  these criteria 
were found to be simpler than the former criteria without compromising 
specificity while slightly increasing sensitivity.  The criteria as proposed 
by Swanton et al. were then incorporated in the revised 2010 McDonald 
criteria (Polman et al. 292-302) (Table 2).
Several other revisions have been made in this latest version of the 
diagnostic criteria: In the 2005 McDonald criteria  DIT was defined as a 
new T2 lesion appearing  on MRI at least 30 days after a reference scan. 
Tur et al. (Tur et al. 631-35) found unchanged specificity when defining 
DIT as a new T2 lesion appearing at any time, as compared to appearing 
within 30 days after the reference. Additionally, it was demonstrated 
(Rovira et al. 587-92) that a single brain MRI could be sufficient to prove 
DIT:  the presence of both enhancing and non-enhancing lesions at the 
same time was shown to be highly specific for CDMS. Furthermore the 
MRI criteria for primary progressive MS (PP-MS) have been adapted: 
DIS can now be accomplished by the presence of  ≥ 1 T2 lesion in a for 
MS characteristic region (periventricular, infratentorial or juxtacortical), 
therefore the  criteria have become more similar to those for relapsing 
MS. This modification results from a study that found a high fulfillment in 
PP MS patients of the DIS criteria as used for RR MS patients, thereby 
suggesting that similar criteria for these two groups of patients are 
feasible (Montalban et al. 1459-65). 
Further modifications concern different subgroups: Neuromyelitis 
optica (NMO) is now recognized as a separate entity because of its 
different clinical course, prognosis, pathophysiology and response to 
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therapy  compared to MS. There is consensus in the 2010 revisions that 
the criteria probably also serve well for pediatric patients that present 
as CIS, but this should still be confirmed in a prospective fashion. 
Recently, the McDonald 2001 MRI criteria were compared to modified 
criteria that require fewer total, fewer periventricular lesions and that omit 
juxtacortical lesions in pediatric patients. These modified criteria were 
found to be somewhat more sensitive than the 2001 McDonald criteria 
while also being highly specific (Callen et al. 961-67). 
Clinical definition of dissemination in space, relation to 
MRI and prognostic evidence
In spite of an increasing role for MRI in diagnosing MS, clinical data 
remain essential.  In contrast to the interpretation of MRI, no clinical 
classification existed up until now.  Therefore a classification system 
to define dissemination in space in more detail was proposed to 
provide further guidance on this subject. In chapter 3.1 we justified this 
classification system by showing that multifocal patients have significantly 
more T2 hyperintense and T1 hypointense (‘black holes’) lesions than 
monofocal patients. Accordingly  ‘clinically multifocal’ is associated with 
more lesions on MRI. In chapter 3.2 we  investigated the prognostic 
value of the classification system. We found that the initial presence of at 
least nine T2 lesions or at least one Gadolinium-enhancing lesion, was 
predictive for time to CDMS in monofocal but not in multifocal patients. 
Therefore in CIS patients with monofocal, but not with multifocal clinical 
presentation, these MRI findings seem to have prognostic value. Possibly 
more pronounced subclinical disease dissemination in monofocal 
CIS patients reflects more active disease, whereas similar findings 
in multifocal patients may be more indicative of prolonged subclinical 
disease evolution. MRI might contribute  less information in these latter 
patients. In addition, we hypothesized that signs not accompanied by 
symptoms from the same location (for example an extensor plantar 
reflex not accompanied by leg motor symptoms) might be due to a past 
episode of inflammation  that has not fully recovered. In these patients 
one might assume a longer subclinical disease history. Aside from 
prognostic information,  a different treatment response in mono and 
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multifocal patients might help in deciding which patients to treat. In the 
same trial, a treatment effect was found for interferon in both groups. 
This effect was more pronounced yet  not significant   in the monofocal 
group. This treatment effect was especially present in monofocal patients 
with ≥ 9 T2 lesions,  compared to monofocal patients with less lesions in 
whom the treatment effect was lower and not significant (Polman et al. 
480-87).  However, all these findings are the result of post hoc analysis 
and still need confirmation. The clinical relevance, with regard to both 
prognosis and treatment effect of the clinical classification system, need 
to be investigated prospective with a longer follow up. 
Future diagnostic criteria may benefit from new MRI techniques and 
different cerebral lesion features. Cortical lesions are not usually seen 
on conventional MR images, even though they contain a large amount 
of lesions. With double inversion recovery (DIR), an MRI technique 
where the signal from white matter as well as from cerebrospinal fluid 
is suppressed, cortical lesions can be more accurately depicted (Filippi 
and Rocca 659-81). These  lesions were present in 30% of a group of 
typical CIS patients. It was shown in this same study that the presence 
of an intracortical lesion is an independent predictor of CDMS, increasing 
specificity in comparison  to the present criteria (Filippi et al. 1988-94). 
Another future MRI characteristic that seems to be  associated with 
conversion to MS and that might have additional value to the Swanton 
criteria, is a lesion in the corpus callosum. This was shown recently 
(Jafari et al. 1837-41) in a group of 158 CIS patients that was followed 
for 39 months. These findings should be further investigated in larger 
multicenter groups of CIS patients, but suggest that the incorporation 
of cortical and corpus callosum lesions in the diagnostic criteria could 
be useful. Another promising MRI technique is scanning with high-field 
strength. Present criteria have been investigated with 1.0 or 1.5 Tesla 
field strength, however   scanning with as much as 7.0 Tesla is now 
possible, even though this is not commonly available. Higher field strength 
has been shown to improve infratentorial lesion detection (Wattjes et 
al. 1159-63). Although 3 Tesla scanning resulted in little improvement 
in  meeting  criteria for dissemination in space in CIS patients in one 
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study (Wattjes et al. 54-59), higher field strength scanning should be 
prospectively evaluated in modified criteria in cohorts of CIS patients. 
Alternatively, the development of specific biomarkers should have 
additional value in future diagnostic criteria. Such biomarkers should 
clearly have (additional) diagnostic value,  yet  should ideally also have 
clinicopathological correlations. An exemplary biomarker is NMO- IgG, 
an antibody that selectively targets the aquaporine-4 water channel. This 
antibody is not only able to distinguish neuromyelitis optica (NMO) from 
MS (Lennon et al. 473-77), but is also implicated in the pathophysiology 
of NMO (Jarius et al. 3072-80;Roemer et al. 1194-205;Takahashi et al. 
1235-43).
Issues remain for patients who present in a less typical manner 
(Rudick 234-36). Some patients are being investigated for other reasons 
than suspected MS, when MRI shows lesions that are highly suspicious 
of the disease. One cannot diagnose MS in these patients due to the 
absence of MS like symptoms. However, a substantial number of these 
develop disease defining symptoms at follow up, and some seem to be at 
high risk for disease progression (Okuda et al. 800-05;Okuda et al. 686-
92). Other patients presenting with a CIS have had previous symptoms 
regarded as atypical. The predictive value for  MS diagnosis and disease 
progression in these subjects should be studied further and incorporated 
in future diagnostic criteria.
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AAN American Academy of Neurology
ALS Amyotrophic Lateral Sclerosis
CIS clinically isolated syndrome
CDMS Clinically Definite Multiple Sclerosis
CNS central nervous system
CSF cerebrospinal fluid
DIS dissemination in space
DIT dissemination in time
DMT disease modifying therapy
IgG immunoglobulin G
ICVD ischemic cerebrovascular disease
IP international panel
MS Multiple Sclerosis
MRI magnetic resonance imaging
NMO Neuromyelitis Optica
OND other neurological disease
PML Progressive Multifocal Encephalopthy
PPMS Primary Progressive Multiple Sclerosis
PRMS Progressive Relapsing Multiple Sclerosis
RRMS Relapsing Remitting Multiple Sclerosis
SPMS Secondary Progressive Multiple Sclerosis
TPHA treponemal hemagglutination
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Multiple Sclerose (MS) is bij jong volwassenen de meest voorkomende 
invaliderende ziekte van het centraal zenuwstelsel.  De meeste patienten 
presenteren zich aan het begin van de ziekte met een acute of sub-
acute episode van klachten, ook wel een ‘clinically isolated syndrome’ 
(CIS) genoemd. Patienten hebben meestal klachten van de oogzenuw, 
het ruggenmerg en/of de hersenstam. Van de patienten die zich met 
een eenmalige episode presenteren krijgt 30-70% uiteindelijk MS en 
daarmee de zogenaamde relapsing remitting vorm van MS (RR-MS). Een 
klein deel van de patienten presenteert zich met langzaam progressieve 
klachten en heeft primair progressieve MS (PP-MS). 
Er is geen eenvoudige diagnostische test om de diagnose te stellen. 
Wel zijn er diagnostische criteria. Om de diagnose MS te kunnen stellen 
is bewijs nodig voor ‘spreiding in ruimte en tijd’ van lesies in het centraal 
zenuwstelsel. Dat betekent dat de klachten en bevindingen bij het 
onderzoek te herleiden moeten zijn tot minimaal 2 plekken in het centrale 
zenuwstelsel (bijvoorbeeld de oogzenuw en het ruggenmerg) op minimaal 
2 verschillende tijdstippen ontstaan. Werd aanvankelijke de diagnose 
vooral met klinische gegevens , evt. een liquorpunctie en/of VEP gesteld, 
de laatste decade is de rol van MRI enorm toegenomen. MRI is het meest 
gevoelige onderzoek voor MS. Bij ca. 95% van de patiënten met MS 
laat de MRI typische afwijkingen zien. Daarnaast is MRI waardevol voor 
het uitsluiten van andere ziektebeelden. De opeenvolgende versies van 
de diagnostische critera bevatten gedetaileerde en steeds verbeterde 
MRI criteria. Bij aanwezigheid van een minimum aantal (nieuwe) lesies 
op voor MS specifieke plaatsen (oorspronkelijk de zgn. Barkhof-Tintore 
criteria) levert de MRI voldoende bewijs voor ‘spreiding in ruimte’ en/of 
‘spreiding in tijd’ en kan zo een deel van het klinische bewijs vervangen 
worden door MRI bevindingen. Zo hoeft vaak niet meer gewacht te 
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worden of en wanneer er een tweede episode van klachten optreedt en 
kan de diagnose sneller gesteld worden. Deze  MRI criteria zijn getest 
in groepen patiënten die zich presenteerden met één episode typische 
MS klachten en vervolgd zijn in de tijd. Van deze patiënten is daardoor 
bekend is of ze  nog een episode MS klachten hebben gekregen. Deze 
studies vinden plaats in gespecialiseerde MS centra en patiënten waarbij 
er in tweede instantie toch verdenking is op een andere ziekte dan MS 
zijn niet geïncludeerd.  In dergelijke patiënten groepen bleken de MRI 
criteria een goede sensitiviteit (zie voor uitleg van deze termen ook box 
1 in hfd. 1 pag.13 ) en specificiteit te hebben voor het ontstaan van een 
tweede episode klachten. Echter, het is onbekend hoe goed deze criteria 
andere ziektebeelden, die zich op een vergelijkbare manier als MS 
kunnen presenteren, uitsluiten. Deze patiénten zijn immers niet in deze 
groepen geïncludeerd. Voor de neuroloog in de dagelijkse praktijk is het 
uitsluiten van andere diagnoses erg belangrijk. Hier gaat het tweede 
hoofdstuk grotendeels over: hoe goed kunnen de diagnostische (MRI) 
criteria de diagnose MS uitsluiten en hoe vaak wordt bij een patiënt 
waarbij bij een second opinie geen diagnose gesteld kon worden alsnog 
een diagnose gesteld. In 2003 heeft de American Academy of Neurology 
(AAN) een stuk gepubliceerd waarin wordt gesteld dat de diagnose MS 
net zo goed te stellen is door 3 T2 lesies op een MRI van de hersenen 
aan te tonen als door het toepassen van de hierboven beschreven MRI 
criteria. Om dit te onderzoeken worden in 2.1 van dit proefschrift de 
MRI criteria zoals in de diagnostische critera staan vergeleken met de 
criteria uit het AAN artikel. Dit wordt gedaan in een groep patiënten die 
in een periode van 3 jaar naar een gespecialiseerd MS centrum werden 
verwezen vanwege een mogelijke MS diagnose.  De verschillende MRI 
criteria worden  toegepast op patiënten uit deze groep die een andere 
diagnose kregen (om te kijken hoe vaak  inderdaad niet aan de criteria 
werd voldaan) en patienten die wel de diagnose MS kregen (om te kijken 
of inderdaad ook aan de criteria werd voldaan). De MRI criteria  zoals 
in de diagnostische richtlijn  staan blijken specifiek terwijl de criteria 
zoals voorgesteld door de AAN dit niet zijn. Desalniettemin blijken de 
diagnostische criteria ingewikkeld voor de dagelijkse praktijk voor zowel 
neurologen als radiologen. In 2005 wordt de richtlijn  aangepast om hem 
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te versimpelen, ruggenmerglesies beter te incorporeren en de diagnose 
sneller, maar net zo betrouwbaar te kunnen stellen. In 2006 worden 
opnieuw aangepaste MRI criteria voorgesteld, de criteria volgens 
Swanton et al., ook dit keer om de diagnose verder te versimpelen. In 2.2 
worden deze MRI criteria volgens Swanton et al. vergeleken met de MRI 
criteria zoals in de 2001 en 2005 McDonald criteria zijn geincorporeerd. 
De Swanton criteria blijken in deze groep even specifiek. In 2.3 worden 
patiënten die geen zekere diagnose kregen bij een second opinion 
wegens een mogelijke MS vervolgd om te kijken bij hoeveel patienten 
in het beloop alsnog een diagnose is gesteld. Dit blijkt bij 15 patienten 
(dit is 4% van de hele patienten groep en 20% van de patienten die 
initieel geen diagnose kregen) het geval te zijn. Zeven patienten kregen 
alsnog de diagnose MS en 8 patienten een andere diagnose waarvan 
bij 4 patienten de andere diagnose cerebrovasculaire ziekte was. 
Hieruit wordt geconcludeerd dat de kans op een andere diagnose na 
een verwijzing naar een tertiair MS centrum klein is. In 2.4 wordt de 
waarde van de MRI gedemonstreerd voor het stellen van een andere 
diagnose bij een verdenking op MS. Er wordt een casus beschreven van 
een patient  met fluctuerende, progressieve sensibiliteitsstoornissen aan 
het been bij wie de diagnose MS is gesteld vanwege witte stof lesies op 
de MRI cerebrum, die echter niet aan de MRI criteria voldoen. Vanwege 
de klinisch mogelijke localisatie in het ruggenmerg wordt een MRI van 
het ruggenmerg gemaakt waarop een schwannoom de oorzaak van de 
klachten blijkt te zijn.  Er wordt een flow chart gesuggereerd voor het 
gebruik van de MRI bij de verdenking op MS.
In hoofdstuk 3 staat een mogelijke  klinische definitie van spreiding 
in ruimte centraal. Hoewel voor de MRI regels zijn opgesteld waaraan 
deze moet voldoen om te mogen spreken van spreiding in ruimte, een 
van de voorwaarden om de diagnose MS te mogen stellen, staat er in 
de diagnosche criteria niet wanneer de bevindingen uit de anamese en 
het lichamelijk onderzoek voldoende zijn om te spreken van spreiding 
in ruimte. Uit eerder onderzoek bleek dat er veel verschillen zijn tussen 
artsen wanneer er sprake is van spreiding in ruimte. In 2005 werd een 
klinisch classificatiesysteem voorgesteld om deze spreiding in ruimte 
uniform te definieren. In dit systeem worden de klachten van patienten 
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en de bevindingen bij lichamelijk onderzoek vertaald naar onderliggende 
lesies en zo bepaald of er sprake zal zijn van één lesie (monofocaal) of 
meer dan één lesie (multifocaal).  In 3.1 wordt dit systeem geëvalueerd 
door het te vergeleken met MRI lesies. Patiënten waarvan de presentatie 
gedefinieerd wordt als monofocaal zouden minder lesies moeten hebben 
dan patienten waarvan de presentatie gedefinieerd wordt als multifocaal 
en zouden minder vaak moeten voldoen aan de criteria voor spreiding 
in ruimte volgens MRI. Hiervoor werden gegevens van alle patiënten 
bij aanvang en van de placebo patiënten over de tijd uit de BENEFIT 
studie gebruikt. In deze studie wordt  interferon beta-1b met placebo 
vergeleken. De geïncludeerde patiënten werden geclassificeerd als 
mono- of multifocaal. De multifocale patiënten bleken inderdaad meer 
T2 lesies en  meer T1 hypointense lesies te hebben en vaker aan de 
MRI criteria voor spreiding in ruimte te voldoen. Er was geen verschil 
in het aantal aankleurende lesies. Hiermee lijkt deze classificatie 
inderdaad klinische betekenis te hebben.  In 3.2 wordt gekeken naar 
de prognostische waarde van het classificatieysteem. Er wordt gekeken 
of er een verschil is in tijd tot een tweede episode van klachten tussen 
mono- en multifocale patiënten. Hierbij worden opnieuw data van 
(placebo) patiënten uit de BENEFIT studie gebruikt. Er blijkt geen 
verschil te zijn tussen mono- en multifocale patiënten in tijd tot een 
tweede episode (ofwel tijd tot CDMS). Wel blijkt het risico op CDMS bij 
monofocale patiënten in 2 jaar groter te zijn als er ≥ 9 T2 of minimaal één 
met gadolinium aankleurende lesie aanwezig is. Bij multifocale patienten 
hebben deze MRI parameters geen voorspellende waarde. Het lijkt er 
dus op dat de MRI bij monofocale patiënten een voorspellende waarde 
heeft, maar niet bij multifocale patiënten. Deze bevindingen wijzen erop 
dat bij patiënten met een CIS een nauwkeurige anamnese en lichamelijk 
onderzoek van belang zijn voor het risico op een tweede episode van 
klachten.  
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